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Abstract 
 
RNA Binding Motif (RBM) domain proteins RBM5 and RBM10 have been shown 
to influence apoptosis, cell cycle arrest and splicing in transformed cells. In this study, 
RBM5 and RBM10 were examined in non-transformed cells in order to gain a wider range 
of knowledge regarding their function. Expression of Rbm5 and Rbm10, as well as select 
splice variants, was examined at the mRNA and protein level throughout H9c2 skeletal 
and cardiac myoblast differentiation. Results suggest that Rbm5 and Rbm10 may (a) be 
involved in regulating cell cycle arrest and apoptosis during skeletal myoblast 
differentiation and (b) undergo post-transcriptional or translational regulation throughout 
myoblast differentiation. All in all, the expression profiles obtained in the course of this 
study will help to suggest a role for Rbm5 and Rbm10 in differentiation, as well as 
possible differentiation-specific target genes with which they may interact. 
 
Keywords 
RNA Binding Motif domain proteins; RBM5; RBM10; H9c2; Myoblast Differentiation; 
Alternative Splicing
iv 
 
 
Acknowledgments 
 
First and foremost, I would like to thank my Supervisor, Dr. Leslie Sutherland. 
Throughout my masters you have given me the opportunity to learn and to experience the 
ins and outs of research, from proposal writing to paper submission, and for this I will be 
forever grateful. The passion and dedication you have towards your students’ learning 
and your research program are unmatched; I am very lucky to have been able to study and 
to grow under your guidance. Thank you also for your friendship and mentoring, which 
have helped me to successfully complete this research project and grow as a researcher. 
I would also like to thank my thesis committee members, Dr. Éric Gauthier, Dr. 
Céline Boudreau-Larivière and Dr. Mazen Saleh, for all of their time and valuable input 
regarding my master’s research project. I am fortunate to have had such a dedicated 
committee, and your perspectives on my work have undoubtedly made my project 
stronger. 
I am very lucky and grateful for the funding I received from the Natural Sciences 
and Engineering Research Council of Canada (NSERC) and the Ontario government, 
which has allowed me to dedicate myself entirely to this project for the past two years. 
Thank you to my lab mates Nina Rintala-Maki and Twinkle Masilamani for 
teaching me various molecular biology lab techniques and for helping me analyze and 
interpret my results. Thank you also to Sarah Tessier, who helped me optimize various 
experimental conditions. I am grateful to have been able to share the joys of successful 
experiments with all of you, and to have had your support and encouragement when those 
times were few and far between. In addition, thank you to all of the members of the 
v 
 
Advanced Medical Research Institute of Canada, particularly the other past and present 
members of the Sutherland lab research group, who have helped me laugh through the 
more difficult days and made the lab feel like a second home. 
A special thank you to my wonderful husband, Mathieu Loiselle, for his 
unwavering support and faith in my abilities, I would not have been able to undertake this 
task without you by my side. Last but not least, thank you to my amazing family and 
friends who have encouraged me every step of the way and helped to keep me balanced 
and focused. The love and support I have received from of all of you means the world to 
me and has given me the strength to take on any new challenges. 
vi 
 
List of Abbreviations 
 
ATRA   All-Trans-Retinoic Ccid 
CASP-2  Caspase 2 
CDK   Cyclin Dependant Kinase 
CDKI   Cyclin Dependant Kinase Inhibitor 
D0 to D7  Day zero to day seven of differentiation 
DM   Differentiation Medium 
GM   Growth Medium 
KD   Knockdown 
LUST   LUCA-15-Specific Transcript 
OE   Overexpression 
PCR   Polymerase Chain Reaction 
qPCR   Quantitative Polymerase Chain Reaction 
Rb   Retinoblastoma  
RBM   RNA Binding Motif 
RT-PCR  Reverse Transcriptase-Polymerase Chain Reaction 
TAE   Tri-Acetate-EDTA 
TNF   Tumour Necrosis Factor 
 
 
vii 
 
Table of contents 
 
Thesis Defence Committee ................................................................................................. ii 
Abstract .............................................................................................................................. iii 
Acknowledgments ............................................................................................................... iv 
List of Abbreviations .......................................................................................................... vi 
Table of contents ............................................................................................................... vii 
List of Figures ...................................................................................................................... x 
List of Tables ...................................................................................................................... xi 
Appendix Index ................................................................................................................. xii 
Chapter 1. Introduction ........................................................................................................ 1 
1.1. RBM5 ............................................................................................................................... 2 
1.1.1. Splice variants ....................................................................................................................... 2 
1.1.2. Structure ................................................................................................................................ 5 
1.1.3. Expression ............................................................................................................................. 5 
1.1.4. Function ................................................................................................................................ 7 
1.2. RBM10 ........................................................................................................................... 11 
1.2.1. Splice variants ..................................................................................................................... 11 
1.2.2. Structure .............................................................................................................................. 12 
1.2.3. Expression ........................................................................................................................... 13 
1.2.4. Function .............................................................................................................................. 13 
1.3. Muscle differentiation model ......................................................................................... 15 
1.3.1. Cell cycle arrest in muscle differentiation ........................................................................... 16 
1.3.2. Apoptosis in muscle differentiation .................................................................................... 19 
1.3.3. Alternative splicing in muscle differentiation ..................................................................... 20 
1.3.4. RBM proteins in muscle ...................................................................................................... 21 
1.4. Models for muscle cell differentiation ........................................................................... 22 
1.4.1. Rbm5 and Rbm10 expression in rat .................................................................................... 25 
1.5. Study Objective .............................................................................................................. 26 
Chapter 2. Materials and Methods ..................................................................................... 27 
2.1. Cell culture and differentiation ........................................................................................... 27 
2.2. RNA extraction ................................................................................................................... 28 
2.3. Reverse Transcription ......................................................................................................... 29 
2.4. Polymerase chain reaction (PCR) ....................................................................................... 32 
viii 
 
2.5. Quantitative PCR (qPCR) ................................................................................................... 32 
2.5.1. Comparative Ct qPCR result quantification method ................................................................... 33 
2.5.2. Relative standard curve qPCR result quantification method ...................................................... 34 
2.6. Transfections ....................................................................................................................... 35 
2.7. Protein extraction and quantification .................................................................................. 35 
2.8. Western blot analysis .......................................................................................................... 36 
Chapter 3. Results - Model Optimization .......................................................................... 39 
3.1. RNA .................................................................................................................................... 40 
3.1.1. qPCR primer efficiency evaluation ............................................................................................. 40 
3.1.2. Validation of comparative Ct quantification method for Rbm5 and Rbm10 splice variant qPCR 
results .................................................................................................................................................... 41 
3.1.3. Validation of the relative standard curve quantification method ................................................ 43 
3.1.4. Reference gene validation for H9c2 skeletal and cardiac myoblast differentiation models ....... 45 
3.2. Cell Differentiation ............................................................................................................. 47 
3.2.1. ATRA Titration .......................................................................................................................... 48 
3.2.2. Confirmation of lineage .............................................................................................................. 51 
3.3. Protein expression analysis ................................................................................................. 54 
3.3.1. Rbm10 band identification .......................................................................................................... 55 
3.3.2. Rbm5 band identification ............................................................................................................ 55 
Chapter 4. Results – Rbm5 and Rbm10 Splice Variant Expression Throughout Rat 
Skeletal and Cardiac Myoblast Differentiation .................................................................. 58 
4.1. Rbm5 splice variant expression analysis ............................................................................. 59 
4.1.1. mRNA and protein expression of full-length Rbm5 did not correlate during myoblast 
differentiation ....................................................................................................................................... 59 
4.1.2. Rbm5+5+6 mRNA expression varied significantly throughout both skeletal and cardiac 
myoblast differentiation ........................................................................................................................ 62 
4.1.3. Lust expression only varied significantly during skeletal muscle differentiation ....................... 63 
4.1.4. Lust mRNA expression was lower than that of full-length Rbm5 and Rbm5+5+6 in rat 
myoblasts .............................................................................................................................................. 64 
4.1.5. Rbm5 splice variants had different expression patterns throughout differentiation .................... 64 
4.2. Rbm10 splice variant expression analysis........................................................................... 66 
4.2.1. Rbm10v1 expression varied only during skeletal muscle differentiation, and only at the protein 
level ...................................................................................................................................................... 66 
4.2.2. Rbm10v2 expression varied most significantly at the protein level throughout both skeletal and 
cardiac myoblast differentiation ........................................................................................................... 69 
4.2.3. Rbm10v2 was more highly expressed than Rbm10v1 in myoblasts, and throughout 
differentiation ....................................................................................................................................... 70 
ix 
 
4.2.4. Rbm10v1 mRNA expression was lower than that of Rbm5 in myoblasts .................................. 72 
Chapter 5. Discussion ........................................................................................................ 73 
5.1. Rbm5 and Rbm10 splice variants are expressed in rat myoblasts ....................................... 74 
5.2. Rbm5 and Rbm10 splice variants are not expressed at the same level in rat myoblasts ..... 74 
5.2.1. In myoblasts, as in transformed cells, Lust expression is lower than that of Rbm5.................... 74 
5.2.2. Unlike in transformed cells, Rbm10v2 expression is higher than that of Rbm10v1 in rat 
myoblasts and throughout myoblast differentiation .............................................................................. 75 
5.3. Possible functions of Rbm5 and Rbm10 splice variants in myoblast differentiation ......... 76 
5.3.1. Rbm5 may be involved in apoptosis and cell cycle arrest .......................................................... 76 
5.3.2. Rbm5+5+6 and Lust may regulate similar cellular events, or each other, throughout skeletal 
myoblast differentiation ........................................................................................................................ 77 
5.3.3. Lust expression, and/or a decrease in Rbm5+5+6 expression may be important to the 
establishment of the cardiac lineage ..................................................................................................... 79 
5.3.4. Rbm10v1 and Rbm10v2 may also be involved in apoptosis and cell cycle arrest events which 
are specific to skeletal muscle differentiation ....................................................................................... 80 
5.3.5. Rbm10v2 may be an important regulator of alternative splicing during cardiac differentiation 81 
5.4. Rbm5, Rbm10v1 and Rbm10v2 may be post-transcriptionally regulated .......................... 81 
5.5. Absence of expression change does not necessarily indicate absence of function ............. 83 
5.6. Conclusion .......................................................................................................................... 84 
References .......................................................................................................................... 86 
 
x 
 
 
List of Figures 
Figure 1. Rat Rbm5 and Rbm10 splice variants examined in this study.. ....................................... 4 
 
Figure 2. Timing of various cellular events throughout H9c2 myoblast skeletal and cardiac 
differentiation. ................................................................................................................................ 17 
 
Figure 3. Primer pair efficiency verification. ................................................................................ 42 
 
Figure 4. Validation of comparative Ct qPCR quantification method for Rbm5 and Rbm10 splice 
variant expression .......................................................................................................................... 44 
 
Figure 5. Reference gene verification ........................................................................................... 46 
 
Figure 6. Cardiac differentiation marker expression following various doses of ATRA. ............ 49 
 
Figure 7. Morphology of differentiating H9c2 cells treated daily with different concentrations of 
ATRA. ............................................................................................................................................ 50 
 
Figure 8. Verfication of lineage - Morphology of differentiating H9c2 cells. .............................. 52 
 
Figure 9. Verification of lineage - mRNA expression of differentiation markers ........................ 53 
 
Figure 10. Rbm5 and Rbm10 western blot band identification .................................................... 56 
 
Figure 11. Rbm5 mRNA splice variant expression throughout H9c2 skeletal and cardiac 
differentiation ................................................................................................................................. 60 
 
Figure 12. Rbm5 protein expression throughout H9c2 skeletal and cardiac differentiation. ........ 61 
 
Figure 13. Rbm10 splice variant expression throughout H9c2 skeletal and cardiac differentiation.
 ....................................................................................................................................................... 67 
 
Figure 14. Rbm10v1 and Rbm10v2 protein expression throughout H9c2 skeletal and cardiac 
differentiation. ................................................................................................................................ 68 
 
Figure 15. Ratio of Rbm10v2/Rbm10v1 protein expression throughout H9c2 skeletal and cardiac 
differentiation. ................................................................................................................................ 71 
 
xi 
 
 
 
List of Tables 
 
Table 1. Primers for RT-PCR and RT-qPCR ................................................................................ 30  
 
Table 2. Raw qPCR data for Rbm5 and Rbm10 splice variant expression at D0 differentiation .. 65 
 
 
 
 
 
xii 
 
Appendix Index 
Summary ........................................................................................................................... A1 
Chapter A1. Introduction .................................................................................................. A2 
Chapter A2. Materials and methods .................................................................................. A4 
A2.1. Stable knockdown. ...........................................................................................................A4 
A2.2. Transient knockdown. ......................................................................................................A7 
A2.3. Transient overexpression .................................................................................................A9 
A2.4. RNA expression analysis. ................................................................................................A9 
A2.5. Protein expression analysis. ...........................................................................................A11 
Chapter A3. Results ........................................................................................................ A12 
A3.1. Rbm5 mRNA knockdown has no effect on Rbm5 protein levels ..................................A12 
A3.2. Rbm5 knockdown correlates with increased Rbm10 protein levels ..............................A12 
A.3.3. Rbm5 overexpression does not correlate with decreased Rbm10 protein levels ..........A16 
Chapter 4A. Discussion .................................................................................................. A21 
A4.1. Only a small quantity of Rbm5 mRNA is translated ......................................................A21 
A4.2. Regulation of Rbm5 protein expression in H9c2/myoblasts has unique characteristics A22 
A.4.3. Decreased Rbm5 mRNA levels regulate Rbm10 protein expression ............................A23 
A4.4. Model .............................................................................................................................A24 
Chapter 5A. Conclusion .................................................................................................. A27 
References ....................................................................................................................... A28 
 
 
1 
 
Chapter 1. Introduction 
 
RNA Binding Motif (RBM) domain proteins are so named due to the presence of 
one or more RNA-Recognition Motif (RRM) domains within their sequence, which 
allows them to interact with specific RNA sequences (Keene & Query, 1991; Sutherland 
et al., 2005). RRM domains are approximately 80 to 100 amino acids in length and can 
vary significantly in sequence, with the exception of two regions whose sequence are 
quite conserved: RNP-2, a hexapeptide, and RNP-1, an octapeptide located about 25 to 35 
amino acids from the C-terminus of RNP-2 (Birney et al., 1993; Burd & Dreyfuss, 1994; 
Sutherland et al., 2005). The large variation in RRM domain sequences means that each 
RRM domain will have its own relatively unique structure and will recognize only 
specific mRNA sequences (Kenan et al., 1991; Sutherland et al., 2005). RBM-containing 
proteins can affect the metabolism of their corresponding RNA molecules in specific 
ways, enabling them to influence various cellular processes (Kim et al., 2009; Sutherland 
et al., 2005). For example, RBM proteins can bind pre-messenger mRNA molecules, 
forming heterogeneous nuclear ribonucleoproteins (hnRNP), which can influence a 
variety of processes such as RNA transcription, pre-mRNA processing and mRNA 
turnover (Dreyfuss et al., 1993; Krecic & Swanson, 1999). RBM proteins can also 
influence alternative splicing and are a component of small nuclear ribonucleoproteins, 
which are important, notably, in pre-mRNA splicing and 3’end processing (Lai et al., 
2003; Zieve & Sauterer, 1990). RBM5 and RBM10 are two examples of such RBM 
proteins. The current study will focus on these two RBM proteins due to their important 
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roles in transformed cells, particularly in regards to modulation of apoptosis and cell 
cycle arrest. 
 
1.1. RBM5 
RBM5 is coded for on the short arm of chromosome 3, in the human lung cancer 
tumor suppressor region (Gazdar et al., 1994; Sutherland et al., 2005). It was first cloned 
as LUCA-15 by Wei at al. in 1996 while searching for genes encoded within this 370-kb 
segment of lung cancer tumor suppressor genes (TSG) located at 3p21.3. Since then, it 
has been cloned by several groups, leading to different names, including LUCA15 
(Edamatsu et al., 2000), H37 (Oh et al., 1999), and RNA-Binding Motif protein 5 
(RBM5) (Timmer et al., 1999).  
 
1.1.1. Splice variants 
The RBM5 gene encodes a transcript of approximately 3000 bp, with an open 
reading frame encoding a sequence of 815 amino acids. Its translational product therefore 
has a predicted molecular weight of 92 kDa, but is detected at between 100 and 120 kDa 
by certain anti-RBM5 antibodies, suggesting that RBM5 protein undergoes post-
translational modifications (Rintala-Maki & Sutherland, 2004; Shu et al., 2007; 
Sutherland et al., 2000; Timmer et al., 1999). Many RBM5 splice variants have been 
identified to date, including RBM5Δ6 in which exon 6 is deleted, RBM5+6 in which 
intron 6 is retained, and RBM5+5+6 in which both introns 5 and 6 are retained 
(Sutherland et al., 2005). Exclusion of exon 6 in RBM5Δ6 causes a frameshift in the 
RBM5 coding sequence and a premature stop sequence in exon 7 (Mourtada-Maarabouni 
et al., 2003). As for both intron-retaining transcripts, protein products of approximately 
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21.5 and 17 kDa, respectively, would be expected due to the presence of stop codons in 
the retained introns (in intron 6 for RBM5+6 and in intron 5 for RBM5+5+6) (Sutherland 
et al., 2005). However, both intron-retaining transcripts and RBM5Δ6 are candidates for 
nonsense-mediated decay, and hence result in no translational product (Maquat & 
Carmichael, 2001; Sutherland et al., 2000). A particularly important observation, 
however, is that there is also a truncated form of RBM5+5+6 (RBM5+5+6t or Clone 26) 
which terminates in intron 6, upstream of the exon 7-8 junction; the transcript therefore 
no longer meets the criteria for nonsense- mediated decay and could yield a translational 
product (Rintala-Maki & Sutherland, 2009). This truncated variant has been previously 
identified in human spleen (Sutherland et al., 2000) and rat fibroblasts (Edamatsu et al., 
2000). 
A non-coding antisense RBM5 transcript has also been identified. This antisense 
transcript was first identified in bone marrow as a 326 bp cDNA fragment. This fragment 
was termed Je2 and its sequence was antisense to that of RBM5+6 (Sutherland et al., 
2000). Later work by Rintala-Maki and Sutherland (2009) investigated whether this 
antisense sequence was part of a larger RBM5 antisense transcript. They did indeed 
identify a 1.4 kb RBM5 antisense transcript which began in intron 6, included intron 5 
and terminated in intron 4 of RBM5, and thus included the Je2 sequence. This longer 
antisense transcript was termed LUST for Luca-15-specific transcript (Rintala-Maki & 
Sutherland, 2009). The current study will focus on RBM5, as well as its splice variants 
RBM5+5+6 and LUST (Figure 1), because the functions ascribed to these particular 
variants, including cell cycle arrest and apoptosis, are important to the model being used 
in the present work. 
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Figure 1. Rat Rbm5 and Rbm10 splice variants examined in this study. A. Rat full-length Rbm5 transcript and select Rbm5 splice variants illustrated based on 
reported human RBM5 splice variant sequences. Lust is an antisense transcript. B. Rat RBM10 splice variants. Exons are represented by correspondingly 
numbered dark grey blocks, and alternatively spliced introns are represented by light grey blocks. Block size does not correspond to exon or intron length. 
Approximate location of forward and reverse primers used for PCR and qPCR are indicated by right and left facing arrows, respectively, on the transcript in 
question.  Size of arrow does not correspond to primer length in relation to exon or intron length, but gives the approximate position of the primer within the 
given exon or intron. Rat-specific sequences were used for primer design. Approximate antibody binding sites are indicated by black ovals with grey slanted 
lines, and the corresponding antibody’s name is indicated. 
Rbm5  
Rbm5+5+6 
Lust 
10 9 8 7 6 5 4 3 2 1 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
4 6 5 3 2 1 
Rbm10 
Variant 1 
Rbm10 
Variant 2 
10 9 8 7 6 5 4 3 2 1 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
10 9 8 7 6 5 3 1 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
A 
B 
Anti-RBM5 LUCA-15UK Antibody  
Anti-RBM5 Abcam Antibody  
Anti-RBM5 SP1 Antibody 
Anti-RBM10 Bethyl Antibody  
4 
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1.1.2. Structure 
RBM5 contains many different functional motifs, including two RMM domains 
(in exons 6 and 10), two bipartite nuclear localisation signals, two zinc finger motifs 
(Mourtada-Maarabouni et al., 2003; Sutherland et al., 2005) and a glycine rich sequence, 
or G-patch domain (Li & Bingham, 1991). In addition, RBM5 has an arginine-rich N-
terminal region, which is believed to be involved in localizing RBM5 to subnuclear 
compartments containing many splicing factors (Aravind & Koonin, 1999). An Octomer 
repeat (OCRE) domain is also contained within the RBM5 sequence, and consists of a 
five-fold repeat of eight residues and a triplet of aromatic amino acids (Callebaut & 
Mornon, 2005). The OCRE domain has been shown to be involved with the regulation of 
splicing once RBM5 has been targeted to the RNA of interest (Bonnal et al., 2008). Taken 
together, these structural components suggest that RBM5 is located in the nucleus and 
affects RNA metabolism. 
 
1.1.3. Expression 
RBM5 and RBM5+5+6 are widely expressed, with the highest expression of 
RBM5, as determined by Northern Blot, being found in the heart, skeletal muscle and 
pancreas (Drabkin et al., 1999; Sutherland et al., 2000; Timmer et al., 1999). Differences 
in RBM5 expression levels been observed between foetal and adult states in the thymus 
and kidney: in adult thymus and fetal kidney RBM5 levels were very high, however they 
were quite low in fetal thymus and adult kidney (Drabkin et al., 1999). Furthermore, older 
fibroblast cell lines and lymphocyte cultures were shown to have higher levels of RBM5 
expression compared to younger cells (Geigl et al., 2004). These results suggest that 
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RBM5 may be important for the development of certain tissues, or maintenance of a 
differentiated cellular state. 
The expression of RBM5 has been shown to be altered in certain transformed 
cells. For example, Oh et al. (2002) reported that in 82% of the primary non-small cell 
lung cancer samples considered, RBM5 transcript levels were lower in the tumour 
samples compared to adjacent normal tissue. RBM5 protein levels were also lower in 
73% of the primary non-small cell lung cancer samples considered, compared to adjacent 
normal bronchial cells (Oh et al., 2002). In addition, RBM5 expression has been reported 
to be decreased in vestibular schwannomas (Welling et al., 2002), cancerous prostatic 
tissues (Zhao et al., 2012), biliary tract cancers (Miller et al., 2009), pancreatic cancers 
(Peng et al., 2013) and stage III serous ovarian carcinomas (Kim et al., 2010). On the 
other hand, in primary breast cancer specimens, expression of RBM5 and Her-2, a proto-
oncogene, were both high, and significantly positively correlated in non-Her-2 
overexpressing tumours (Oh et al., 1999; Rintala-Maki et al., 2007). Furthermore, 
overexpression of Her-2, in the breast cancer cell line MCF-7 and in the ovarian cancer 
cell line CaOv-3, increased levels of RBM5 mRNA (Oh et al., 1999). However, in another 
case, RBM5 expression was seen to be decreased in breast cancer cells (Edamatsu et al., 
2000). Therefore, RBM5 expression in breast cancer samples may depend on an as-yet-
unidentified variable.  
Another important consideration with regards to RBM5 expression is that Je2 (a 
portion of the antisense transcript LUST) has been shown to negatively affect the levels of 
full-length RBM5 (Mourtada-Maarabouni et al., 2002; Rintala-Maki & Sutherland, 2009). 
Inversely, overexpression of the full-length LUST was shown to increase RBM5+5+6 
levels and to lower RBM5+5+6t levels (the truncated form). A model in which the 
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transcription termination signal leading to the transcription of RBM5+5+6t is masked by 
LUST, thus increasing levels of RBM5+5+6 and decreasing the levels of RBM5+5+6t 
upon LUST overexpression ,was proposed and gives an interesting perspective on how 
RBM5 splice variants may regulate their own expression (Rintala-Maki & Sutherland, 
2009).  
 
1.1.4. Function 
RBM5 is a putative tumour suppressor gene. In fact, RBM5 was found to be one of 
nine genes down regulated in metastasis and part of the 17 common gene signatures 
associated with metastasis in various solid tumour types (Ramaswamy et al., 2003). In 
addition, a microarray analysis of 5603 genes showed that when RBM5 was 
overexpressed in CEM-C7 cells, a human leukemic cell line, the expression of 35 genes 
involved in proliferation and apoptosis was changed (Mourtada-Maarabouni et al., 2006). 
Included in these differentially expressed genes were (a) Cyclin-dependent kinase 2 
(CDK2), which is necessary for G1/S transition during cell cycle progression, (b) Signal 
transducer and activator of transcription 5B (STAT5b), which is important for many 
cellular processes including apoptosis, and (c) Bone morphogenic protein 5, which is 
notably important in organ development (Baśkiewicz-Masiuk & Machaliński, 2004; 
Golden et al., 1999; Mourtada-Maarabouni et al., 2006). Interestingly, overexpression of 
a portion of Lust decreased RBM5 levels. It also caused opposite changes in the 
expression of six of the genes whose expression was initially found to be modulated by 
RBM5 overexpression in the microarray experiment (Mourtada-Maarabouni et al., 2006; 
Mourtada-Maarabouni & Williams, 2006). These findings support the previous statement 
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that RBM5 antisense transcript works, at least in part, to downregulate the expression of 
the full-length RBM5 variant. 
The role of RBM5 in cell cycle arrest and apoptosis has been thoroughly 
investigated. In CEM-C7 cells, the overexpression of RBM5 was shown to suppress cell 
proliferation, and stable RBM5 transfectants were arrested in the G1 phase of the cell 
cycle (Mourtada-Maarabouni et al., 2003). RBM5 also induced apoptosis and cell cycle 
arrest at the G1 phase in A549 cells, a non-small cell lung cancer cell line (Oh et al., 
2006). Growth inhibition and increased apoptosis levels following RBM5 overexpression 
was seen in PC-3 cells, a human prostate cancer cell line, as well (Zhao et al., 2012). In 
addition, RBM5 overexpression suppressed growth of human fibrosarcoma HT1080 cells 
(Edamatsu et al., 2000) and increased p53-mediated inhibition of cell growth of H1299 
cells (non-small cell lung cancer cell line) (Kobayashi et al., 2011). When RBM5 was 
ectopically expressed in mouse fibroblast A9 cells, which were then injected into nude 
mice, tumour growth was even retarded (Oh et al., 2002). Furthermore, overexpression of 
full-length RBM5 in Jurkat human T lymphoblastoid cells enhanced apoptosis induced by 
various death receptor ligands including Fas, TNF-α, and TRAIL (Rintala-Maki & 
Sutherland, 2004; Sutherland et al., 2000). Similar results were observed upon 
investigation of RBM5 expression in clones of the breast cancer cell line MCF-7: loss of 
RBM5 and decreased susceptibility to death upon exposure to TNF-α were positively 
correlated (Rintala-Maki et al., 2004). Furthermore, overexpression of exogenous RBM5 
in these cells increased their sensitivity to TNF-α mediated apoptosis (Rintala-Maki et al., 
2004). These results therefore suggest that RBM5 is involved in inducing cell cycle arrest 
and modulating apoptosis. This can be accomplished through a number of different 
pathways and holds true in a variety of cell lines. 
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RBM5 splice variants have also been shown to influence the cell cycle and 
apoptosis. For instance, Jurkat cells stably transfected with RBM5+5+6t (Clone 26) 
showed a reduced growth rate and increased sensitivity to Fas-mediated apoptosis 
(Sutherland et al., 2000). In addition, decreased expression of RBM5 and Clone 26 was 
seen in Rat-1 cells, in which Ras, a small GTPase which is responsible for the activation 
of genes involved in cell growth and differentiation, was constitutively expressed 
(Edamatsu et al., 2000). These results suggest that RBM5+5+6t, like RBM5, functions to 
enhance cell cycle arrest and apoptosis.   
With regards to antisense RBM5 expression, however, the opposite effect to 
RBM5 and RBM5+5+6 expression in regards to modulation of the cell cycle and 
apoptosis is observed. For example, in CEM-C7 cells, stable expression of a portion of 
LUST inhibited Fas-mediated apoptosis (Mourtada-Maarabouni et al., 2001). 
Furthermore, in Jurkat cells LUST also inhibited Fas and TNF-α mediated apoptosis 
(Sutherland et al., 2001). It was also demonstrated that expression of the small antisense 
transcript and Bcl-xL, an apoptotic inhibitor, were positively correlated (Mourtada-
Maarabouni et al., 2006). Therefore, antisense RBM5 expression seems to protect cells 
from certain types of apoptosis mediated by RBM5 or RBM5+5+6t. 
As previously mentioned, RBM5 can bind RNA molecules due to the specific 
domains contained in its sequence, and has been shown, to date, to specifically regulate 
the alternative splicing of six different genes. One such gene is caspase 2 (CASP-2). In 
this case, RBM5 has been shown to bind to a sequence within intron 9 of the CASP-2 pre-
mRNA, and by doing so excluded exon 9 from the mature transcript (Fushimi et al., 
2008). This resulted in an increase in the levels of the proapoptotic CASP-2 variant. 
Conversely, when exon 9 is retained, the resulting full-length CASP-2 does not promote 
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apoptosis (Fushimi et al., 2008). RBM5 has also been shown to be involved in the 
regulation of Fas alternative splicing. More precisely, RBM5 promotes exclusion of exon 
6 in the Fas mRNA, and consequently increases the levels of soluble Fas, the variant 
which does not promote apoptosis (in contrast to the retention of exon 6, which leads to 
the translation of a membrane bound, pro-apoptotic Fas receptor) (Bonnal et al., 2008). 
Furthermore, RBM5 has been shown to influence the alternative splicing of c-FLIP by 
promoting the exclusion of exon 7 (Bonnal et al., 2008). This leads to increased levels of 
c-FLIP(L) which can regulate apoptosis (Chang et al., 2002). These examples suggest that 
RBM5 may modulate apoptosis, at least in part, by influencing the alternative splicing of 
specific apoptosis-related factors. However, in these examples, its effects on apoptosis 
were contradictory: RBM5 promoted the exclusion of exon 9 in CASP-2 (leading to 
translation of the pro-apoptotic variant) and promoted the exclusion of exon 6 and 7 in 
Fas and c-FLIP, respectively (leading to translation of the variant which does not 
promote apoptosis). In addition, RBM5 was shown to increase expression of a putative 
oncogenic isoform of Activation-induced cytidine deaminase (AID) by promoting exon 4 
skipping in the AID pre-mRNA (Jin et al., 2012).  
The two other genes whose alternative splicing has been shown to be regulated by 
RBM5 are Abscisic Acid Insensitive3 (ABI3) and Dystrophin. Firstly, in Arabidopsis 
thaliana, the suppressor of abi3-5 (SAU – an homologue of RBM5) was shown to 
decrease splicing of a cryptic intron in the AIB3 pre-mRNA (Sugliani et al., 2010). Thus, 
RBM5 increased levels of the full length ABI3 transcript (ABI3-α) which is important for 
seed maturation, and decreased levels of its splice variant (ABI3-β) (Nambara et al., 1995; 
Sugliani et al., 2010). In regards to dystrophin, RBM5 was shown to enhance the skipping 
of exons 40 and 72 (O’Leary et al., 2009). Dystrophin expression is important for muscle 
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health and a loss of dystrophin protein expression, as seen in patients with Duchenne 
Muscular Dystrophy (DMD), causes muscle wasting and usually death early in life 
(Koenig et al., 1987; Muntoni, 2003). In some cases of DMD however, dystrophin exon 
skipping was shown to restore an at least partially functional form of dystrophin, leading 
to a less serious phenotype (van Deutekom et al., 2007). The involvement of RBM5 in the 
alternative splicing of ABI3 and dystrophin suggests a potential role for RBM5 as a 
developmental regulator.  
 Taken together, expression and functional data currently published regarding 
RBM5 point to its function as a regulator of apoptosis and of cell cycle arrest through its 
influence on alternative splicing. RBM5+5+6t has been shown to have similar effects on 
the cell as RBM5, whereas the antisense transcript generally affect the cell in an opposite 
manner. 
 
1.2. RBM10 
RBM10 is another RBM domain-containing protein and is located on the X 
chromosome at position p11.23 (Coleman et al., 1996; Thiselton et al., 2002). Through 
the process of X chromosome inactivation, one RBM10 allele is inactivated, however, the 
remaining allele is highly expressed in human cell lines and mouse tissue (Coleman et al., 
1996). RBM10 was first cloned from bone marrow in 1995 and has 49% amino acid 
sequence homology with RBM5 (Nagase et al., 1995; Sutherland et al., 2005). 
 
1.2.1. Splice variants 
Three RBM10 variants have been identified in humans (Sutherland et al., 2005; 
Wang et al., 2012). The two main RBM10 splice variants, which are also widely 
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expressed, are RBM10 variant 1 (RBM10v1) and RBM10 variant 2 (RBM10v2) 
(Sutherland et al., 2005) (Figure 1). The mRNA encoding RBM10v1 is made up of 24 
exons and codes for a protein product of approximately 930 amino acids (Johnston et al., 
2010). The mRNA encoding RBM10v2 lacks exon 4, resulting in a protein product of 
approximately 853 amino acids (Johnston et al., 2010). Protein products from both 
variants can be detected via Western Blot analysis, at approximately 103 and 94.7 kDa, 
respectively. The mRNA encoding RBM10 variant 3 (Genbank accession number: 
AK024839) was identified in primary smooth muscle cells, has an alternate transcription 
start site and a deletion of 23 bp in exon 4 which causes a frameshift and consequently a 
premature stop codon within the modified exon (Wang et al., 2012). The current study 
will focus on RBM10v1 and RBM10v2, due to their wide expression and because the 
functional data reported for these two variants is also of relevance to the model used in 
this study. 
 
1.2.2. Structure 
Similar to RBM5, RBM10 contains two RRM domains, a G-patch sequence and 
two zinc finger motifs (Sutherland et al., 2005). Comparison of amino acid sequences 
between RBM5 and RBM10 reveals a 49% and 53% identity between RBM5 and the two 
RBM10 variants, respectively (Sutherland et al., 2005). However, three exons are 
particularly different between RBM5 and RBM10: (a) exon 4, which is completely 
different between RBM5 and RBM10v1, and absent in RBM10v2, and (b) exons 9 and 
15, which are identical in both RBM10 variants, but hold only 14% homology to RBM5 
(Sutherland et al., 2005). Due to their high level of homology, RBM5 and RBM10 may 
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be involved in similar cellular processes. However, since they do have exons with quite 
different sequences, they may also have different functions in the cell. 
 
1.2.3. Expression 
As mentioned previously, RBM10 is highly expressed in human cell lines and 
tissues, as well as in mouse tissues (Coleman et al., 1996). Of particular interest to this 
study, RBM10 expression has been detected consistently in heart and skeletal muscle, no 
matter the detection method used as graphed by GeneCards (www.genecards.org/cgi-
bin/carddisp.pl?gene=RBM10&search=rbm10). Furthermore, expression of a non-
mutated form of RBM10 is important since mutations in its sequence have been shown to 
be linked with TARP syndrome. The acronym of this syndrome describes some of its 
associated symptoms: talipes equinovarus, atrial septal defect, Robin sequence 
(characterized by micrognathia, glossoptosis and cleft pallet) and persistence of the left 
superior vena cava (Johnston et al., 2010). This rare pleiotropic developmental 
abnormality syndrome has been reported to cause death before or soon after birth 
(Johnston et al., 2010). RBM10 has also been shown to be truncated in lung 
adenocarcinomas (Imielinski et al., 2012) and mutated in pancreatic intraductal papillary 
mucinous neoplasms (Furukawa et al., 2011). These findings confirm the importance of a 
non-mutated RBM10 gene in the cell, and even suggest a potential role for RBM10 in 
development. 
 
1.2.4. Function 
As reviewed by Sutherland et al. in 2005, at that point no functional studies 
regarding RBM10 had been undertaken. However, since then, some studies have begun to 
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examine the expression pattern of RBM10 under specific conditions, and explore the 
effects of manipulating RBM10 expression on cellular processes. For example, in primary 
chondrocytes induced to hypertrophy, RBM10 expression was shown to be elevated, 
which was accompanied by an increase in apoptosis and a decrease in proliferation 
(James et al., 2007). Also, in breast cancer samples, it was shown by RT-PCR that the 
expression of RBM10 and caspase-3, a protein important in apoptosis, were positively 
correlated (Martín-Garabato et al., 2008). Furthermore, also in breast cancer samples, 
RBM10v1 expression was correlated with the expression of proapoptotic BAX and tumour 
suppressor p53 (Martínez-Arribas et al., 2006). This study also showed that RBM10v1 
and RBM10v2 expression was correlated with that of vascular endothelial growth factor 
(VEGF), which stimulates the growth of new blood vessels. Together, these findings 
suggest that RBM10 may not only play a role in modulating apoptosis and cell cycle 
arrest, as shown for RBM5, but that RBM10 may also be important in controlling 
angiogenesis. 
In addition, a recent paper by the Sutherland group showed a strong link between 
RBM10 expression and TNF-α mediated apoptosis: RBM10 knockdown decreased levels 
of both TNF-α mRNA and soluble TNF-α (sTNF- α) protein, as well as decreased the 
cells’ sensitivity to TNF-α mediated apoptosis (Wang et al., 2012). The overexpression of 
RBM10 had the expected reverse effect, with increased levels of TNF-α mRNA and 
sTNF-α protein, as well as increased apoptosis. These investigators also showed that 
increased TNF-α mRNA expression upon RBM10 overexpression was associated with 
increased TNF-α transcription, and not simply stabilization of the corresponding mRNA. 
These results further support the possibility that RBM10 does in fact work as a modulator 
of apoptosis, and that its effects are mediated, at least in part, by TNF-α. 
15 
 
Potentially linked to its role in apoptosis and cell cycle modulation, RBM10 has 
also been shown to affect alternative splicing: RBM10 knock-down influenced the 
alternative splicing of many factors important in various cellular processes (unpublished 
data). RBM10 has also been purified from pre-spliceosomal complexes (Behzadnia et al., 
2007; Deckert et al., 2006). Furthermore, as previously described, RBM5 expression was 
shown to favour exclusion of exon 6 in the Fas receptor (Bonnal et al., 2008); however, 
decreased RBM5 expression was not sufficient to change Fas receptor pre-mRNA 
splicing. Decreased RBM5, RBM10 and RBM6 levels were associated with preferential 
inclusion of exon 6 in Fas (Bonnal et al., 2008). These results suggest that RBM10, like 
RBM5, plays a role in alternative splicing. 
Most of the work previously reported concerning RBM5 and RBM10 has been 
performed in transformed cells. Therefore, it is not yet known if these functions occur in 
non-transformed systems as well, or if they are a consequence of the transformed state of 
the cells. One particularly useful non-transformed model in which to study RBM5 and 
RBM10 is myoblast differentiation, since many of the events which have been associated 
to RBM5 and RBM10 in transformed cells also occur during differentiation (i.e., 
alternative splicing, apoptosis and cell cycle arrest). Furthermore, as described above, 
Rbm5 and RBM10 have been shown to be highly expressed in skeletal and heart muscle, 
and have a potential link to development (Drabkin et al., 1999; Johnston et al., 2010). 
 
1.3. Muscle differentiation model 
Differentiation involves the modulation of complex mechanisms. This leads to the 
transcription and translation of specific genes, whose downstream effects allow the 
differentiating cells to become specialized in a particular function (di Giacomo et al., 
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2010). In terms of muscle cell differentiation, it is during early embryogenesis that cells 
from specific sections of the mesoderm become committed as skeletal and cardiac 
myoblasts, respectively, and then differentiate to form specialized myocytes (Yahi et al., 
2006). During this differentiation from myoblast to myocyte, cells follow a highly 
ordered process involving cell cycle withdrawal and important metabolic and structural 
changes (Yahi et al., 2006; di Giacomo et al., 2010) (Figure 2). For example, during 
skeletal muscle differentiation, cells enter into the differentiation pathway, undergo 
irreversible cell cycle withdrawal, express specific contractile apparatus and metabolic 
factors, and finally fuse to form multinucleated myotubes (Andrés & Walsh, 1996). Three 
notable events that occur during differentiation from myoblast to myocyte are cell cycle 
arrest, apoptosis and alternative splicing. These three cellular events have also been 
shown to be modulated to a certain degree by RBM5 and RBM10 in transformed cells. 
Therefore it is specifically on these steps of differentiation, and their timing in the 
differentiation process, that this study will focus.  
 
1.3.1. Cell cycle arrest in muscle differentiation 
 Cell cycle progression requires specific mitogenic signals to be expressed in a 
precisely regulated manner (Ahuja et al., 2007). In muscle differentiation, myoblasts must 
exit the cell cycle before expression of components of the contractile system can occur, 
which begins at around 48 hours after induction of differentiation (Andrés & Walsh, 
1996; Yahi et al., 2006). Therefore, cell cycle arrest is one of the first events involved in 
muscle differentiation. For example, in skeletal muscle differentiation, within 24 hours 
after induction of differentiation, factors such as myogenin, a transcription factor
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Figure 2. Timing of various cellular events throughout H9c2 skeletal and cardiac myoblast differentiation. Approximate timing of various events involved 
in H9c2 skeletal and cardiac myoblast differentiation. Timing of events based on information documented for H9c2 and other cell lines. Events indicated in gray 
are specific to skeletal muscle differentiation, while events indicated in black occur during both skeletal and cardiac muscle differentiation. 
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involved in regulating skeletal muscle differentiation, and cyclin dependent kinase 
inhibitor (CDKI) p21 are expressed and lead to downstream permanent cell cycle arrest in 
differentiating myoblasts (Andrés & Walsh, 1996; Walsh & Perlman, 1997). The 
expression of other cell cycle inhibitors, such as the CDKI p27 and p57, is also 
upregulated in the first days of skeletal muscle cell differentiation, while the expression of 
cell cycle activators, such as cyclin-dependent kinases (CDK) and cyclins, is 
downregulated (Martelli et al., 1994; Yahi et al., 2006). Expression of retinoblastoma 
protein (pRb) is also essential for cell cycle arrest during skeletal muscle differentiation: 
without its expression cell cycle arrest is not observed and apoptosis levels increase 
(Novitch et al., 1996; Zacksenhaus et al., 1996). Therefore, many factors are involved in 
the terminal cell cycle arrest observed within the first two to three days of skeletal muscle 
differentiation. 
In cardiac differentiation, as in skeletal muscle differentiation, a key first step is 
cell cycle arrest. The cell cycle arrest involved in cardiac differentiation occurs in the G1 
phase and involves regulation of similar factors, including upregulation of pRb, CDKI 
p21 and p27, as well as down regulation of several positive cell cycle regulators such as 
cyclin A (Ahuja et al., 2007; Koh et al., 1998; Poolman et al., 1998). However, in cardiac 
differentiation, cell cycle arrest is not permanent for fetal myoblasts: cardiac myocytes 
continue to proliferate in foetal life and terminal cell cycle arrest occurs only later, 
usually post-natality (Ahuja et al., 2007; Li et al., 1997). Therefore, in cardiac 
differentiation, although cells do not divide during differentiation from cardiac myoblast 
to myocyte in the foetus, once differentiated, they do retain a certain mitotic ability 
(Hayashi & Inoue, 2007; Li et al., 1997; Menard, 1999). This study will focus on the 
differentiation of myoblasts to myocytes.  
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1.3.2. Apoptosis in muscle differentiation 
Apoptosis is a type of programmed cell death which occurs in all tissues (Ellis et 
al., 1991). It is also a normal part of differentiation (Fidziańska & Goebel, 1991), and has 
been documented during differentiation of both primary myoblast cultures (Sandri et al., 
1996), and established myoblast cell lines (Wang & Walsh, 1996). During muscle cell 
differentiation, the peak of apoptotic activity occurs at approximately 24 to 48 hours after 
the induction of differentiation, hence around the same time as cell cycle arrest (Wang & 
Walsh, 1996). It is thought that apoptosis is necessary in order to remove excess 
myoblasts (Miller & Stockdale, 1986), with the ability to escape apoptosis being linked to 
cell cycle exit: cells not differentiating and thus not undergoing subsequent cell cycle 
arrest would be targets for apoptosis (Fujio et al., 1999; Wang & Walsh, 1996). This is 
logical since myoblasts are susceptible to mitogen-deprivation induced apoptosis which 
occurs during differentiation, whereas terminally differentiated myocytes are not (Wang 
et al., 1997).  
Many factors have been shown to be involved in the modulation of apoptosis 
during muscle differentiation. For example, cells with increased expression of CDK 
inhibitor p21 and dephosphorylated pRb have been shown to undergo cell cycle arrest and 
to adopt an apoptotic-resistant status (Walsh & Perlman, 1997; Wang et al., 1997; Wang 
& Walsh, 1996). This is logical since, as mentioned above, p21 and pRb are important for 
cell cycle arrest, therefore myoblasts expressing these factors would presumably be 
differentiating, hence not subjected to apoptosis.  
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1.3.3. Alternative splicing in muscle differentiation 
Alternative splicing is a step in the pre-mRNA maturation process in which 
certain exons are preferentially retained or excluded, to produce many different mRNA 
transcripts from one gene (Black, 2003; Chen & Manley, 2009). This process therefore 
significantly increases the number of different mature transcripts that can be produced 
from a single gene, and even more so, from a genome: 98% of human multi-exonic pre-
mRNAs are alternatively spliced (Pan et al., 2008; Wang et al., 2008). Proteins resulting 
from the alternative splicing of the same pre-mRNA can sometimes have different or 
even opposing functions. Therefore, alternative splicing, and not simply gene expression, 
can play a very important role in regulating a variety of cellular processes, including cell 
differentiation, migration, growth and apoptosis (Revil et al., 2010). Of particular interest 
for this study is a report which examined alternative splicing during mouse early 
embryonic development. This study showed that across developmental stages and tissues, 
alternative splicing and specific isoform expression occurs at high rates and is even 
comparable to changes in whole-transcript expression (Revil et al., 2010). This study also 
showed that the mRNA expression of known splicing factors significantly changed during 
early embryonic development. This suggests that a large part of the temporal and spatial 
regulation of isoform expression during differentiation is performed by specific splicing 
factors. 
Alternative splicing is particularly important during muscle differentiation. For 
example, one study showed that 63 important alternative splicing events occurred in three 
distinct temporal patterns during mouse heart development (Kalsotra et al., 2008). They 
also showed that the levels of certain splicing factors changed during this differentiation 
process: for example, CUG-BP and ETR-3-like factor (CELF) protein was down-
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regulated 10-fold, and muscleblind-like 1 (MBNL1) protein was up-regulated almost 4-
fold. Furthermore, more than half of the observed alternative splicing events were also 
conserved in chicken heart development, suggesting their importance to developmental 
processes. Such results were also seen throughout mouse skeletal muscle differentiation 
(C2C12 cell line): significant splicing transitions were seen in 95 alternative splicing 
events, and more than half of these transitions were also conserved during avian myoblast 
differentiation (Bland et al., 2010). In summary, not only does muscle differentiation 
require exact spatial and temporal gene expression, but also necessitates precise 
regulation of the alternative splicing of these transcriptional products by specific splicing 
factors (Revil et al., 2010). 
 
1.3.4. RBM proteins in muscle 
Certain RBM proteins have already been shown to play a role in differentiation, or 
have emerged in various differentiation-related screens and arrays. For example, 
expression of RBM9 isoforms, also known as Fox-2, was found to change significantly 
during early embryogenesis (Revil et al., 2010). This may be associated with the reported 
role of RBM9 as a regulator of alternative splicing in neurons and muscle cells (Nakahata 
& Kawamoto, 2005). Many other RNA binding proteins have also been shown to vary in 
their expression throughout differentiation, such as Rbm13, Rbms3 and Rbm19 (Revil et 
al., 2010).  
 RBM4 and RBM20 are two RBM proteins which have been shown to play a role 
notably in muscle cell differentiation. First, RBM4 was shown to favor the inclusion of 
muscle-specific exons in tropomyosin, and thus increase the expression of the skeletal 
muscle-specific α-tropomyosin isoform during myogenic differentiation (Lin & Tarn, 
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2005). Overexpression of Rbm4 in C2C12 cells was also shown to promote the 
expression of muscle cell specific, or differentiation-induced, transcript isoforms of many 
genes including cardiac troponin T, insulin receptor, and ryanodine receptor (Lin & Tarn, 
2011). In regards to RBM20, it was found to be involved in the regulation of splicing of 
over 30 genes, many of which are involved in cardiac physiology and disease, such as 
titin, in both rats and humans (Guo et al., 2012). Therefore, it is known that certain RBM 
proteins are particularly important to differentiation, and even muscle cell differentiation, 
with this role varying depending on the protein in question. However, the possible role of 
many other RBM proteins in this physiological process still remains to be evaluated, and 
many myoblast cell lines are available for such studies.  
 
1.4. Models for muscle cell differentiation  
Several muscle cell lines have been established which allow the in vitro study of 
muscle cell differentiation from myoblast to myocyte. The advantage of many of these 
cell lines is that they are secondary cell lines and thus are not transformed. This means 
that the division potential of these myoblasts has not been altered during the 
establishment of the cell line: the normal growth, differentiation and lifespan of these 
cells should be very close to that of myoblasts present in the organism of origin. Since the 
cells are not transformed, however, they will only divide a limited number of times and 
may eventually lose some of their characteristics. This is in contrast to (a) primary cells 
which are obtained directly from an organism and only grow in culture for a very short 
period of time (one or two divisions), and (b) immortalized cell lines, which have been 
transformed as such that the cells are able to divide indefinitely. These immortalized cell 
lines may be considered cancer cell lines, depending on certain characteristics such as 
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their ability to form colonies of cells in soft agar (a hallmark of cancer is anchorage 
independent growth) (Hanahan & Weinberg, 2000). Therefore, the advantage of 
secondary muscle cell lines is that they can be cultured in the lab and retain many of the 
characteristics of the cells from the tissue of which they originate. This can be very 
important when studying processes such as apoptosis and cell cycle arrest in myoblast 
differentiation, since these phenomena are generally altered in transformed cells. 
Thus, these muscle differentiation models mimic quite accurately the in vivo 
processes which occur during differentiation, including cell cycle withdrawal, expression 
of muscle specific proteins, and even cellular morphological changes (Pownall et al., 
2002; Sabourin & Rudnicki, 2000). Usually cell confluence and/or serum deprivation 
triggers myogenic differentiation in these cultures of myoblasts (Pownall et al., 2002). 
However, the timing of the resulting cascade of events will be different depending on if 
differentiation was induced by cell confluence or serum deprivation: differentiation 
occurs faster when cells are switched from normal growth medium to reduced serum 
medium (as opposed to prolonged culture in normal growth medium, which leads to cell 
confluence), the lag time being approximately 24 hours for C2C12 cells (Dee et al., 
2002). The fact that both cell confluence and serum deprivation can trigger differentiation 
makes consistent and appropriate culture conditions essential in order to avoid the 
untimely differentiation of the myoblasts.    
Examples of myoblast cell lines which can be used to study differentiation include 
the Rat L6 cell line which was derived from primary cultures of rat thigh muscle and can 
be induced to differentiate into skeletal myocytes upon growth medium serum reduction 
(Vandromme et al., 1992; Yaffe, 1968). The C2C12 cell line, which are murine myoblasts 
derived from C3H mice thigh muscle subjected to a crush injury, can also be induced to 
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differentiate into skeletal myocytes upon serum reduction (Blau et al., 1983; Burattini et 
al., 2004). A particularly interesting cell line is the H9c2 cell line, which was derived 
from embryonic BDIX rat heart tissue (Hescheler et al., 1991; Kimes & Brandt, 1976). 
Depending on their differentiation treatment, these myoblasts have the particular ability to 
differentiate into either skeletal or cardiac myocytes: upon only serum reduction skeletal 
muscle differentiation is induced however, when serum reduction is accompanied by 
treatments with a specific compound, like all-trans-retinoic acid (ATRA), cardiac 
differentiation is induced (Kimes & Brandt, 1976; Menard, 1999). Therefore, although 
H9c2 cells are derived from heart tissue, they have the ability to transdifferentiate and 
acquire a skeletal muscle cell phenotype (Brostrom et al., 2000; Menard, 1999). Therefore 
two muscle cell lineages can be studied within the same cell line and compared. This is a 
particularly useful characteristic, especially in expression studies, since it facilitates an 
evaluation of whether the expression of a certain gene is specific to a lineage, or how 
expression might change between lineages, providing additional information on the 
potential role of a gene of interest. For instance, if a gene’s expression changes in a 
certain way during the establishment of only one of the lineages, based on documented 
differences between lineages, it is possible to narrow down potential functions for the 
gene. 
Important differences between skeletal and cardiac muscle lineages exist. Firstly, 
embryonic cardiomyocytes can re-enter the cell cycle after undergoing their initial 
differentiation (Kageyama et al., 2002). Therefore cell cycle arrest is not permanent after 
cardiac differentiation in foetal life, unlike skeletal muscle differentiation in which cell 
cycle arrest is permanent (Kageyama et al., 2002). Secondly, different transcription 
factors are activated depending on the lineage, such as MyoD and myogenin, which are 
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specifically activated during skeletal muscle differentiation (Miner & Wold, 1990). It is 
important to take into account the differences between skeletal and cardiac muscle 
lineages when comparing expression results between these lineages.  
 
1.4.1. Rbm5 and Rbm10 expression in rat 
The H9c2 cell line used for this study was derived from rat tissue. As of yet, not 
all described RBM5 and RBM10 splice variants identified in humans have been reported 
in rat. Only full length Rbm5 mRNA and protein have been identified in rat, and this, 
notably in the spleen (Accession numbers BC166477 and AAI66477, respectively) 
(Strausberg et al., 2002). In addition, Rbm5 mRNA expression has been identified and 
studied in Rat-1 cells, a rat fibroblast 3T3 like cell line (Edamatsu et al., 2000). In that 
study, Rbm5 mRNA was found to be downregulated by Ras, a protein involved in the 
activation of certain proto-oncogenes. This result is consistent with what has been 
reported in regards to RBM5 in transformed cells, implicating RBM5 in tumour growth 
suppression. However, there have been no reports, to our knowledge, on the expression of 
the Rbm5 splice variants Rbm5+5+6 and Lust in rat myoblasts. In regards to Rbm10, only 
one mRNA sequence, corresponding to Rbm10v2, is reported in the National Centre for 
Biotechnology Information (NCBI) nucleotide database and was derived from rat liver 
samples (Accession number NM_152861) (Inoue et al., 1996). However, both Rbm10v1 
and Rbm10v2 translational products (with the accession numbers EDL97699 and 
NP_6090600, respectively) have been previously identified in rat tissue (Florea et al., 
2005; Inoue et al., 1996). 
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1.5. Study Objective 
RBM5 and RBM10 have been quite extensively studied in transformed systems. 
However, it is unknown if they play the same roles in non-transformed systems, or if 
these functions are a cause or a consequence of the transformed state. Therefore, we set 
out to first investigate the expression of RBM5 and RBM10 in a normal/non-transformed 
model. The system chosen for this work was the H9c2 differentiation model since RBM5 
and RBM10 (a) are highly expressed in cardiac and skeletal muscle cells, and (b) have 
been associated with cell cycle arrest, apoptosis and alternative splicing in transformed 
cells, all processes also important to myoblast differentiation (Figure 2). The main 
objective of this study was to determine the mRNA and protein expression of Rbm5 and 
Rbm10 splice variants throughout the first seven days of H9c2 skeletal and cardiac 
myoblast differentiation, respectively. Subsequently, the expression results were to be 
compared within a lineage, and between both lineages. This was done as a first step in 
determining if Rbm5 and Rbm10 play a role in this non-transformed system, and what 
this role may involve, based on the temporal expression of the Rbm5 and Rbm10 genes 
(RNA and protein). We hypothesized that Rbm5 and Rbm10 have similar functions in 
transformed and non-transformed cells, and thus that they would be involved in cell cycle 
arrest, apoptosis and alternative splicing in differentiating cells. We therefore anticipated 
that increases in their expression levels would be seen at days when such cellular events 
occur in differentiating cells, i.e., at days two and three of differentiation, when cell cycle 
arrest and apoptosis occur at their maximum. We also expected that the mRNA and 
protein expression patterns of Rbm5 and Rbm10 splice variants would positively 
correlate during differentiation, if their regulation was at the transcriptional level.  
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Chapter 2. Materials and Methods 
 
2.1. Cell culture and differentiation 
H9c2 cells were purchased from ATCC (catalogue number: CRL-1446) and 
cultured in growth medium (GM) consisting of Dulbecco’s Modified Eagle Medium (Life 
Technologies, Burlington, ON) supplemented with 10% foetal bovine serum (FBS) (Life 
Technologies) and 4 mM of L-Glutamine (Life Technologies). Cells were passed when 
they reached 75% confluency and GM was replaced every two days. 
H9c2 cells were differentiated once they reached approximately 65% confluency, 
and within passage 16 to 20. Skeletal muscle differentiation was induced by reducing GM 
FBS concentration from 10% to 1% (Brostrom et al., 2000; Karagiannis et al., 2010). This 
reduced serum medium will be referred to as differentiation medium (DM). Cardiac 
differentiation was also induced by switching cells from GM to DM (Brostrom et al., 
2000; Karagiannis et al., 2010), but this switch was accompanied by daily treatments of 
10 nM ATRA (Sigma-Aldrich, Oakville, ON), as described by Ménard et al. (Menard, 
1999). To verify successful differentiation into the desired lineage, the mRNA expression 
of skeletal muscle differentiation marker myogenin (Myog) (Edmondson & Olson, 1989; 
Kee et al., 2007) and cardiac differentiation marker myosin light chain 2 (Myl2) were 
evaluated (Bettiol et al., 2007). Differentiation day zero (D0) refers to the day at which 
the cells were first exposed to reduced serum medium (and ATRA in the case of cardiac 
differentiation). Cells were not passaged after being induced to differentiate, but DM was 
changed every two days. 
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Optimization of the ATRA concentration to be used in order to maximize the 
yield in cardiomyocytes was accomplished by administering daily ATRA concentrations 
of 0, 10, 20, 50 or 100 nM, respectively, to the differentiating cells. mRNA expression of 
cardiac differentiation markers Myl2 and Troponin T type 2 (cardiac) (Tnnt2) were then 
examined by RT-qPCR at D5 differentiation (Bettiol et al., 2007; Ng et al., 2010). 
 
2.2. RNA extraction 
RNA extraction was performed using Tri-Reagent (Molecular Research Centre, 
Inc., USA), according to the manufacturer’s instructions. Bromochloropropane (Sigma-
Aldrich) was used for phase separation. RNA pellets were resuspended in special TE (10 
mM of Tris-HCl, 0.1 mM EDTA, DEPC-treated water) supplemented with RNaseOUT 
(Life Technologies). RNA quantity was measured by spectrophotometry (Model Du530, 
Beckman Coulter, Mississauga, ON). To insure that there was no protein contamination 
in the RNA samples, their 260 nm/280 nm absorbance ratio was also evaluated, and only 
samples with ratios of 1.8 and above were used (Bustin & Nolan, 2004; Pfaffl, 2005). To 
verify RNA quality, 1 µg of each RNA sample was subjected to electrophoresis through a 
1% Tris-Acetate-EDTA (TAE) agarose gel stained with SYBR Safe DNA gel stain (Life 
Technologies). Two crisp and clear bands, representing 28S and 18S rRNA, respectively, 
had to have been seen at approximately a 2.0 ratio on the stained gel, with low amounts of 
small fragments, for the RNA sample to be used in future experiments (Bustin & Nolan, 
2004; Pfaffl, 2005). 
Before the RNA samples were reverse-transcribed, genomic DNA contamination 
was evaluated by amplification of actin from the RNA samples via polymerase chain 
reaction (PCR) with 40 amplification cycles (Table 1). The experimental procedure for 
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the PCR reaction is explained below. Visualization of a product when the PCR reaction 
was separated by electrophoresis through a 2% TAE agarose gel indicated genomic 
contamination. If genomic contamination was found, the Turbo DNA-free kit (Ambion, 
USA) was used on all samples from that biological replicate, according to the 
manufacturer’s instructions for rigorous DNase treatments. Following Turbo DNA-free 
treatment, a second actin amplification reaction was performed on the RNA samples to 
ensure the treatment was effective.  
 
2.3. Reverse Transcription 
 Reverse transcription was performed using 1 µg of RNA, 1 µL of dNTP mix (10 
mM) (Life Technologies), 1 µL of oligodT (500ng/µL) (AlphaDNA, Montreal, QC) and 
distilled water for a total volume of 12 µL. The mixture was heated to 65˚C for 5 minutes 
and quickly chilled on ice. Next, 2 µL of DTT (0.1M) (Life Technologies) and 4 µL of 
5X First Strand Buffer (Life Technologies) were added. After a two minute incubation at 
42˚C, 1 µL of Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV-RT) 
(Life Technologies) was added. A 50 minute incubation at 42˚C followed, and the 
reaction was then inactivated by heating at 70˚C for 15 minutes. For examination of 
strand-specific Rbm5 transcripts Rbm5+5+6 and Lust, strand specific cDNAs were 
prepared. The steps involved in strand-specific cDNA synthesis were the same as 
described above, except (a) 1 µL of the gene-specific RT primer (10 µM) (Table 1) 
(AlphaDNA) was added instead of oligodT in the first step, and (b)
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Table 1. Primers for RT-PCR and RT-qPCR 
Gene 
name 
Splice 
variant Primers  Homology 
Actb  Forward 5’ TGAGCGCAAGTACTCTGTGTGGAT 3’ R M 
  Reverse 5’ TAGAAGCATTTGCGGTGCACGATG 3’ R 
  Product size in rat 129 bp  
  Annealing  Temperature 62˚C  
  Accession No. Rat: NM_031144, Mouse: BC138611, Human: BC001301  
     
Tnnt2  Forward 5’ CTCCAAAACTCGTGGGAAGG 3’ R M 
  Reverse 5’ TCTGCATCGGGTGCCTGGCA 3’ R 
  Product size in rat 136 bp  
  Annealing Temperature 66.1˚C  
  Accession No. Rat: BC161855, Mouse: L47599, Human: BC002653  
     
Myl2  Forward 5’ CCTGACGTCACCGGCAACC 3’ R 
  Reverse 5’ CCTGGGGATGGAGAACAGGC 3’ R 
  Product size in rat 122 bp  
  Annealing Temperature 60˚C  
  Accession No. Rat: BC126064, Mouse: BC061144, Human: BC105821  
     
Myog  Forward 5’ CAACTGAGATTGTCTGCCAGGC 3’ R 
  Reverse 5’ GTCTTATGTGAATGGACGGTGGG 3’ R 
  Product size in rat 165 bp  
  Annealing Temperature 63˚C  
  Accession No. Rat: M24393, Mouse: BC048683, Human: BC053899  
     
Gapdh  Forward 5’ ACCACAGTCCATGCCATCAC 3’ R M H 
  Reverse 5’ TCCACCACCCTGTTGCTGTA 3’ R M H 
  Product size in rat 452 bp  
  Annealing Temperature 58˚C  
     
  Forward 5’ ATGTTTGTGATGGGTGTGAA 3’ R M 
  Reverse 5’ ATGCCAAAGTTGTCATGGAT 3’ R M 
  Product size in rat 122 bp  
  Annealing Temperature 62.7˚C  
  Accession No. Rat: BC059110, Mouse: BC082592, Human: BC004109  
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Rps12  Forward 5’ TGAGCCCATGTATGTCAAGCTGGT 3’ R M 
  Reverse 5’ ACTACAACGCAACTGCAACCAACC 3’ R 
  Product size in rat 162 bp  
  Annealing Temperature 67˚C  
  Accession No. Rat: M18547, Mouse: X15962, Human: BC017321  
     
Rbm5 Rbm5 Forward 5’ GTGTAAGCCGTGGTTTCGC 3’ R M H 
  Reverse 5’ TTGCAATGTGCTTTCCTTGA 3’ R M H 
  Product size 108 bp  
  Annealing Temperature 60˚C  
  Accession No. Rat: BC166477, Mouse: BC023854, Human: AF091263  
     
 Rbm5+5+6  Reverse Transcription 5’ AAACTCTACTTGGTCCTTAACA 3’ R 
  Forward 5’ TAACCTCTTCCCAACTGATTACATTC 3’ R 
  Reverse  5’ CATCTGAGAAGTTATGCCTCTA 3’ R 
  Product size in rat 176 bp  
  Annealing Temperature 63˚C  
  Accession No. Rat: NC_005107, Mouse: NC_000075, Human: AB586690  
     
 Lust Reverse Transcription 5’ TCTGACCTTTAAGATAAATGTA 3’ R 
  Forward 5’ CATCTGAGAAGTTATGCCTCTA 3’ R 
  Reverse 5’ TAACCTCTTCCCAACTGATTACATTC 3’ R 
  Product Size in rat 176 bp  
  Annealing Temperature 63˚C  
  Accession No. Rat: NC_005107, Mouse: NC_000075, Human: EF470865  
     
Rbm10 Variant 1 Forward 5’ CCCCAGAGACGGCGACTATC 3’ R M 
  Reverse 5’ CCTGTGGCAGCATCCTCAGC 3’ R M H 
  Product size in rat 128 bp  
  Annealing Temperature 60˚C  
  Accession No. Rat: F1LWMO, Mouse: BC004674, Human: BC004181  
     
 Variant 2 Forward 5’ ATTGGCTCCCGTCGAACTAACAGT 3’ R 
  Reverse 5’ ACTTCTCTCGGCGCTTGAAGTTCT 3’ R M 
  Product size in rat 682 bp  
  Annealing Temperature 63˚C  
  Accession No. Rat: NM_152861,Mouse: NM_001167776, Human: NM_152856 
H, R, M indicate homology to human, rat and mouse sequences, respectively
32 
 
SuperScript II reverse transcriptase (Life Technologies) enzyme was used instead of 
MMLV-RT. 
 
2.4. Polymerase chain reaction (PCR) 
cDNA amplification by PCR was performed in BioRad iCycler thermocyclers 
(Mississauga, ON) using 1 µL of cDNA, 1 µL of the corresponding forward and reverse 
primers (10 µM) (Figure 1, Table 1), respectively, 1 µL of dNTP mix (10 µM), 2 µL of 
10X Buffer (New England Biolabs, Whitby, ON), 1 µL of Taq DNA polymerase 
(500U/mL) (New England Biolabs) and sterile distilled water for a total volume of 15 µL 
per reaction. The number and duration of PCR cycles for actin, Gapdh and Rbm10v2 were 
as follows: (1) one cycle of 95ºC for 5 minutes, (2) gene-specific cycle number of 95ºC 
for 30 seconds, primer-specific annealing temperature (Table 1) for 30 seconds, and 72ºC 
for 45 seconds, and (3) one final extension cycle of 72ºC for 10 minutes. PCR products 
were analyzed by TAE agarose gel electrophoresis, and gels were stained with SYBR 
Safe DNA Gel Stain. Densitometric analysis was performed using AlphaEase FC 
software (Alpha Innotec). It is important to note that the mRNA expression values 
obtained for each day of differentiation, for each biological replicate, were first expressed 
normalized to Gapdh, then expressed as fold-change from their respective D0 expression 
values. Following this, the average of the normalized fold-change in expression, for all 
three biological replicates, was determined for each day of differentiation and graphed. 
 
2.5. Quantitative PCR (qPCR) 
qPCR analysis was performed using the Applied Biosystems 7900HT Fast Real-
Time PCR System. Sample reactions were prepared using 5 µL of cDNA sample diluted 
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as required, 12.5 µL of 2x Power SYBR Green PCR Master Mix (Applied Biosystems, 
Burlington, ON), 1 µL of the corresponding forward and reverse primers (10 µM) 
(AlphaDNA) (Figure 1, Table 1), respectively, and sterile distilled water for a total 
volume of 25 µL per reaction. The qPCR reaction program included (1) one cycle of 95ºC 
for 10 minutes, (2) 40 cycles of 95ºC for 30 seconds, primer-specific annealing 
temperature (Table 1) for 30 seconds and 72ºC for 15 seconds, and (3) one dissociation 
curve cycle of 95ºC for 15 seconds, primer-specific annealing temperature for 15 seconds, 
and 95ºC for 15 seconds. Standard curves were prepared using serial dilutions of pooled 
cDNA from samples of the respective biological replicate. The efficiency of each primer 
pair was determined as previously described based on the slope of their corresponding 
standard curve (Schmittgen & Livak, 2008). Potential reference genes Rps12 and Gapdh 
were screened as previously described (Schmittgen & Zakrajsek, 2000).  
 
2.5.1. Comparative Ct qPCR result quantification method  
The 2-∆∆Ct equation was used to determine the normalized mRNA expression 
value for Rbm5 and Rbm10 splice variants, relative to D0 differentiation, for each day of 
differentiation, in each biological replicate. Ct refers to the cycle threshold (Ct) of a 
sample and thus indicates the number of PCR cycles required for the number of amplicon 
copies to reach the set threshold value. Hence, a gene’s Ct is inversely proportional to its 
expression in the sample of interest. The equation used for comparative Ct qPCR 
quantification was described in Applied Biosystems User Bulletin No. 2 (P/N 4303859). 
In this case, ∆∆Ct = [Ct, target (day of differentiation) – Ct, reference (day of 
differentiation)] – [Ct, target, D0 of differentiation) – Ct, reference (D0 of 
differentiation)]. The normalized relative expression value was determined for each day 
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of differentiation within a biological replicate, and then averaged between all biological 
replicates and graphed. This ensured that observed changes in gene expression were only 
the result of the differentiation conditions administered to the cells, and not due to any 
previous cell culture conditions. This also ensured consistency throughout biological 
replicates. Also, with this quantification method, changes in expression between 2 and 0.5 
fold were not considered for statistical significance since it is the sensitivity limit for this 
type of qPCR quantification analysis: variations between 2 and 0.5 fold can be expected, 
but larger variations may be significant (Karlen et al., 2007). 
 
2.5.2. Relative standard curve qPCR result quantification method 
The relative expression level of differentiation markers in specific samples was 
calculated using the ABI software (SDS 2.4) and uses the formula log 10^((Ct(sample)-y 
intercept)/(-slope)) to calculate concentrations. Based on the standard curve of the gene of 
interest, its relative expression level in the samples was determined. To normalize these 
values, the relative expression of the gene of interest in each biological replicate was 
divided by the geometric mean of the expression of the reference genes in the 
corresponding sample. These normalized gene expression values were then divided by the 
normalized D0 expression value for that biological replicate, to get the fold-change in 
expression from D0 differentiation. These fold-change values were then averaged for the 
various biological replicates and plotted. Again, this ensured that observed changes in 
expression were only due to differentiation conditions administered to cells, and not 
previous culture conditions of that biological replicate. 
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2.6. Transfections 
The plasmids used for the transient overexpression of RBM5, RBM10v1 and 
RBM10v2, respectively, were pcDNA3.RBM5, pcDNA3.RBM10v1 and 
pcDNA3.RBM10v2, with pcDNA3 as the negative control. Note, RBM5, RBM10v1 and 
RBM10v2 sequences were human. 
Cells in GM were passaged such that a confluency of 35% would be obtained on 
the day of the experiment. At that point, 12 µg of the respective pcDNA3 plasmid and 18 
µL of Lipofectamine 2000 Transfection Reagent (Life Technologies) were each mixed 
separately with 1.5 ml of Opti-MEM reduced serum medium with GlutaMAX (Life 
Technologies). After a 5 minute incubation at room temperature, the DNA+Opti-MEM 
and Lipofectamine 2000+Opti-MEM mixtures were mixed together, and incubated at 
room temperature for 20 minutes. Following this, the transfection mixture was added to 
the cells. The medium was not changed after addition of the transfection mixture, and cell 
pellets were collected at 48 and/or 72 hours post-transfection. 
 
2.7. Protein extraction and quantification 
Cell pellets were resuspended in cell lysis buffer (50 mM Tris-HCl pH 8.0, 150 
mM NaCl, 0.5% NP-40, 100 mM NaF, 1 mM EDTA pH 8.0, 1 mM EGTA pH 7.5, 10 
µL/mL of 100X protease inhibitor cocktail [Sigma-Aldrich]), and centrifuged at 14,000 x 
g for 10 minutes. Protein quantification was performed using the BioRad DC Protein 
Assay Kit and a SpectraMax 340PC384 absorbance microplate reader (Molecular 
Devices, Downingtown, PA, USA).  
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2.8. Western blot analysis 
Protein samples were prepared as previously described (Sutherland et al., 2000). 
Prior to loading, protein samples were diluted 1:2 in Western sample buffer (0.06 M Tris-
HCl pH 6.8, 25% glycerol, 2% SDS, 0.01% bromophenol blue [BioRad], 5% 2-
mercaptoethanol [ThermoFisher Scientific, Ottawa, ON]) and heated to 95ºC for at least 
four minutes. Twenty-five microliters of Precision Plus protein ladder (BioRad) or 50 µg 
of the appropriate protein sample was loaded, per lane, onto polyacrylamide gels. Seven 
percent resolving gels (0.37 M Tris pH 8.8, 0.1% SDS, 7% acrylamide [BioRad], 0.1% 
APS, 0.1% TEMED [BioRad]) and four percent stacking gels (0.1 M Tris pH 6.8, 0.1% 
SDS, 4% acrylamide, 0.05% APS, 0.1% TEMED) were used. Gels were run in running 
buffer (0.025M Tris, 0.19M glycine, 0.1% SDS) at 100V until samples ran through the 
stacking gel (approximately 1.5 hours), and then at 200V until the dye front ran off the 
bottom of the resolving gel (approximately 4 hours). Following gel electrophoresis, the 
proteins were transferred to a PVDF membrane (0.45 µm pore size) (GE Health Care, 
Mississauga, ON) using a wet transfer apparatus for 90 minutes at 350 mA in transfer 
buffer (25 nM Tris, 192 mM glycine, 20% methanol). Transfer efficiency was verified by 
staining with Ponceau S (Sigma-Aldrich). Following transfer, membranes were washed in 
three times in TBS-T (20 mM Tris, 0.5 M NaCl, 0.1% Tween-20) (one 15 minute wash, 
followed by two 5 minute washes). Membranes were then blocked for 1 hour, at room 
temperature, in TBS-T supplemented with 5% non-fat dry milk (BioRad). Next, the 
membranes were washed three times with TBS-T (one 15 minutes wash, followed by two 
5 minute washes), and incubated overnight, at 4˚C, with a primary antibody diluted in 
TBS-T supplemented with 3% non-fat dry milk. The primary antibodies used were mouse 
anti-rat-α-tubulin (1:10,000, sc-8035, Santa Cruz Biotechnologies Inc., Santa Cruz, CA), 
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rabbit anti-rat-RBM10 (1:1000, A301-006A, Bethyl Laboratories Inc/Cedarlane, 
Burlington, Canada), rabbit anti-rat-RBM5 (1:2500, ab85504, Abcam, Toronto, ON), 
rabbit anti-rat-RBM5 LUCA-15UK (1:2000, non-commercially available [Sutherland et 
al., 2000]) and rabbit anti-rat-RBM5 SP1 (1:1000, non-commercially available [Bonnal et 
al., 2008]).  
Following the incubation with the primary antibody, the membranes were washed 
three times with TBS-T (one 15 minute wash, followed by two 5 minutes washes), and 
incubated 1 hour, at room temperature, with their corresponding secondary antibody 
diluted in TBS-T supplemented with 3% non-fat dry milk. A goat anti-mouse HRP-
conjugated secondary antibody (1:20,000, sc-2005, Santa Cruz Biotechnologies Inc.) and 
a goat anti-rabbit HRP-conjugated secondary antibody (1:10,000, sc-2004, Santa Cruz 
Biotechnologies Inc.) were employed. The presence of antibodies on the membrane was 
detected using Amersham ECL Western Blotting Detection Reagents (GE Healthcare) 
and Amersham Hyperfilm ECL (GE Healthcare).  
The membranes were stripped between probing with different primary antibodies 
by being washed twice for 10 minutes in mild stripping buffer (1.5% glycine, 0.1 % SDS, 
0.1% Tween 20, pH 2.2), twice for 10 minutes in phosphate-buffered saline (1x PBS, pH 
7.4, Life Technologies), and finally twice for 5 minutes with TBS-T. Since all anti-RBM5 
antibodies used were raised in rabbit, blots were covered with ECL and exposed for 30 
minutes after each strip, to ensure stripping efficiency. Quantification of the signal was 
performed using the AlphaEase FC software (Alpha Innotech) and the values were 
normalized to α-tubulin. It is important to note that, just as with the determination of 
Rbm5 and Rbm10 mRNA expression, protein expression values obtained for each day of 
differentiation for a specific biological replicate were first normalized to α-tubulin, then 
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expressed as fold-change from their respective D0 expression values. Following this, the 
average of the normalized fold-change in expression values, for all three biological 
replicates, was determined. This ensured that any observed expression changes were not 
due to any previous cultures conditions, and only to the differentiation procedures 
administered. 
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Chapter 3. Results - Model Optimization  
Since Rbm5 and Rbm10 have not yet been studied in rat muscle cells, many 
optimization steps were required prior to examining their splice variant mRNA and 
protein expression throughout rat skeletal and cardiac myoblast differentiation. The three 
main factors requiring optimization, which will be described in this chapter, were (a) 
RNA quantification techniques, (b) cell culture and differentiation procedures, and (c) 
protein expression analysis. First, in order to correctly determine and analyze Rbm5 and 
Rbm10 mRNA expression throughout differentiation, optimal qPCR primers and 
amplification conditions had to be determined for all genes of interest, including 
differentiation markers and reference genes. Furthermore, as described, not all Rbm5 and 
Rbm10 variants being analyzed have previously been documented in H9c2 cells, therefore 
it was necessary to verify that our primer sets would allow the detection of specific 
alternative splicing products if they are expressed in the cells. Appropriate housekeeping 
genes also had to be found for our model of study, and gene quantification methods for 
qPCR data analysis had to be validated. 
In regards to cell culture and differentiation, differentiation conditions had to be 
tested and the optimal ATRA concentration for differentiation into cardiomyocytes had to 
be determined. Differentiation into the desired cell lineage was confirmed by examining 
the expression of specific cardiac and skeletal muscle differentiation markers myosin 
light chain 2 regulatory subunit and myogenin, respectively. This was important since it 
ensured that the desired muscle lineage was in fact achieved in the various samples. 
Finally, protein overexpression experiments were performed using various 
antibodies in order to determine which bands on a Western blot did in fact correspond to 
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the various Rbm5 and Rbm10 splice variants studied. This was a necessary step since 
many bands were being detected around the expected molecular mass of our proteins of 
interest. Therefore, identification of the appropriate protein band was necessary before 
attempting the quantification of protein levels during myocyte differentiation. 
 
3.1. RNA 
First, the efficiency of the qPCR primers had to be verified to ensure the 
expression of their corresponding gene was in fact correctly represented in the subsequent 
qPCR result (Pfaffl, 2006; Souazé et al.,1996). Also, the method used for qPCR gene 
expression quantification, comparative Ct or relative standard curve analysis, had to be 
validated for the genes of interest. This is an important step since each method has 
particular criteria which need to be met before it can be used to quantify the expression of 
a gene based on qPCR data. Finally, the expression of specific housekeeping genes had to 
be examined throughout the differentiation processes to ensure that their expression did 
not change, and they were therefore good reference genes to use in our models. Without 
proper verification, the expression of our genes of interest could be misinterpreted 
(Schmittgen & Zakrajsek, 2000). All of these factors had to be addressed before Rbm5 
and Rbm10 mRNA expression analysis could take place. 
 
3.1.1. qPCR primer efficiency evaluation 
qPCR primer efficiencies had to be verified and be above 1.6 to be considered for 
future use in qPCR experiments. This would ensure correct representation of the 
expression of their corresponding gene in qPCR results (Pfaffl, 2006; Souazé et al., 
1996). The efficiency of each qPCR primer pair was determined (Figure 3) based on the 
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slope of their standard curve. Since all primer sets had efficiencies above 1.6, they could 
all be used to determine the expression of their corresponding gene in qPCR experiments 
(Pfaffl, 2006; Souazé et al., 1996).  
 
3.1.2. Validation of comparative Ct quantification method for Rbm5 and Rbm10 splice 
variant qPCR results 
The advantage of the comparative Ct quantification method is that data can be 
presented as fold-change from a control sample, or in this case, from D0 differentiation. 
This is particularly useful when evaluating Rbm5 and Rbm10 expression throughout 
differentiation, since we are looking for rapid and significant changes in expression from 
our reference sample (D0) and between two consecutive days of differentiation in a 
particular lineage. However, specific criteria must be met since this quantification method 
uses only a sample’s Ct value for the calculation of gene expression (unlike the relative 
standard curve quantification method , a standard curve for the primer pair in question is 
not necessary). Notably, the efficiencies of the target and reference genes must be 
between approximately 1.8 and 2.2, and within approximately 10% of each other 
(Applied Biosystems, 2008; Livak & Schmittgen, 2001). This ensures that the expression 
of each gene is correctly represented. To determine if the efficiencies of the primer pairs 
are sufficiently close, the Ct of the gene of interest and potential reference genes are 
obtained using dilutions of pooled sample cDNA. The difference between Ct Target and Ct 
Reference vs. log of input cDNA quantity is then graphed, and the slope of the trendline must 
be less than 0.1 in order for the comparative Ct quantification method to be used for the 
genes in question (Applied Biosystems, 2008). First, we determined that the Gapdh,
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Figure 3. Primer pair efficiency verification. Standard curves of various primer pairs used for the 
amplification of the corresponding genes (Table 1). A. Standard curves for Rbm5 and Rbm10 splice 
variants studied. B. Standard curves for differentiation markers Myl2, MyoG, and Tnnt2, and potential 
reference genes Gapdh and Rps12. Standard curves constructed from RT-qPCR results of the corresponding 
primer pair and pooled dilutions of sample cDNA. Corresponding equation of the best-fit linear trendline is 
indicated. R2 represents the correlation coefficient of the trendline, and E represents the efficiency of the 
corresponding primer pair. Data shown for biological triplicates, done in technical duplicate. Error bars 
represent standard error.
qPCR primer efficiency verification for differentiation markers and 
potential housekeeping genes 
Myl2, y= -2.9x + 26.4, R2 = 0.996, E = 2.22 
Myog, y= -3.5x + 15.3, R2 = 0.9956, E = 1.92 
Rps12, y= -4.5x + 16.5, R2 = 0.9997, E = 1.67 
Gapdh, y= -3.2x + 14.3, R2 = 0.9999, E = 2.06 
qPCR primer efficiency verification for Rbm5 and Rbm10 splice variants 
Tnnt2, y= -4.4x + 15.1, R2 = 0.9987, E = 1.68 
A 
B 
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Rbm5 and Rbm10 primer pairs had efficiencies within the required range (Figure 3). Also, 
the slope of the (Ct Target - Ct Reference) vs. log of input cDNA graph trendline was less than 
0.1 for all four Rbm5 and Rbm10 splice variant primer pairs tested, when normalized to 
Gapdh (Figure 4). Therefore, the efficiencies of the target and reference genes were 
sufficiently close and the comparative Ct quantification method could be used to quantify 
the mRNA expression of Rbm5 and Rbm10 splice variants in our differentiation samples. 
It is important to note that the efficiency of Rps12 (1.67) was not within the necessary 
range (1.8-2.2) for this type of quantification method, therefore it was not considered as a 
candidate for gene expression normalization.  
 
3.1.3. Validation of the relative standard curve quantification method  
The relative standard curve quantification analysis method is particularly useful 
when determining the relative expression of a gene in a sample when there is no control 
sample from which we can express their expression as fold-change. Therefore, this 
method was useful for determining the expression of differentiation markers: we could 
use it, for example, to compare the expression of markers only at D5 differentiation 
between lineages and replicates. This quantification method uses the standard curve 
obtained for a primer pair to determine the expression of the corresponding gene in a 
sample, as described in Chapter 2. Since it uses the slope and y-intercept of a primer 
pair’s standard curve to extrapolate a sample’s relative expression of the gene of interest, 
the difference in efficiencies between the target and reference gene’s primers can be 
greater than that permitted with the comparative Ct quantification method, but all must be 
above 1.6 (Pfaffl, 2006; Schmittgen & Livak, 2008; Souazé et al., 1996). Since the 
efficiencies of all differentiation markers and both potential reference gene efficiencies  
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Figure 4. Validation of comparative Ct qPCR quantification method for Rbm5 and Rbm10 splice 
variant expression. RT-qPCR data for the expression of various Rbm5 splice variants, Rbm10v1 and 
Gapdh in dilutions of pooled cDNA. Expression is graphed as change in Ct of gene of interest from Gapdh, 
which is used to normalize. Equation of the best-fit trendline is indicated on the graph. Data shown is from 
three biological replicates, performed in technical quadruplicate.
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were within this range (Figure 3B), this qPCR quantification could be and was used to quantify the mRNA expression of all 
differentiation markers used in this study. 
 
3.1.4. Reference gene validation for H9c2 skeletal and cardiac myoblast differentiation models 
Reference genes must be validated before studying gene expression in a system which does not already have specific and well 
established reference genes. One such method includes determining the Ct value of the potential reference gene, by qPCR, throughout 
the experimental conditions. The Ct values are then expressed as a fold-change from the reference sample (D0 differentiation in this 
case), and a one-way ANOVA is performed: if there is a statistically significant change in the expression of the reference gene 
throughout the experimental condition, it is not a suitable reference gene for the system (Schmittgen & Zakrajsek, 2000). This method 
of reference gene validation was performed in this study to evaluate whether Gapdh and Rps12 were appropriate reference genes for 
the H9c2 skeletal and cardiac myoblast differentiation models. Since p > 0.05 for the one-way ANOVA on Gapdh and Rps12 
expression throughout skeletal and cardiac myoblast differentiation (Figure 5), Gapdh and Rps12 expression did not change 
significantly during the establishment of either lineage. Therefore, both Gapdh and Rps12 were suitable genes for the normalization of 
gene expression throughout both lineages.  
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Figure 5. Reference gene verification.  Expression of two potential reference genes, Gapdh (A, C) and Rps12 (B, D), was examined throughout both 
experimental conditions: H9c2 skeletal (A, B) and cardiac (C, D) myoblast differentiation. RT-qPCR results of the fold-change in Ct values from D0 
differentiation are graphed for D1 through D7 of differentiation. Data shown are from three biological replicates, performed in technical quadruplicate. Indicated 
p-value is from a one-way ANOVA performed on graphed data. Changes in expression throughout a differentiation lineage were considered statistically 
significant if p < 0.05. 
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3.2. Cell Differentiation  
H9c2 myoblast differentiation into skeletal and cardiac myocytes has been 
extensively studied (Brostrom et al., 2000; Karagiannis et al., 2010; L’Ecuyer et al., 2001; 
Menard, 1999). However, to ensure maximum cardiomyocyte yield, we optimized the 
concentration of ATRA administered to the cells. Since it is the ATRA that prevents 
H9c2 cells from transdifferentiating to skeletal myocytes upon serum reduction, higher 
ATRA concentrations should decrease the number of cells transdifferentiating to skeletal 
myocytes, and maximize cardiomyocyte yield. However, too high a concentration of 
ATRA could be toxic due to its pleiotropic effects (Germain et al., 2006). The mRNA 
expression of the cardiac markers Myl2 and Tnnt2 was used to quantify cardiac 
differentiation in a cell population (Bettiol et al., 2007; Karagiannis et al., 2010; Ng et al., 
2010; Pereira et al., 2011). In addition, cells were observed by phase-contrast microscopy 
to determine if the administered ATRA concentration had a visible effect on cell 
morphology.  
The proportion of skeletal versus cardiac muscle cells in each biological replicate 
was determined once differentiation procedures were optimized. To this end, cells were 
observed by phase contrast microscopy and the expression of skeletal muscle 
differentiation marker Myog and cardiac differentiation marker Myl2 were determined. 
Measuring the expression of differentiation markers also allowed quantification of the 
degree of skeletal and cardiac muscle differentiation in each replicate. Again, lineage had 
to be confirmed to ensure that treatment of cells successfully produced skeletal or cardiac 
myocytes, respectively.  
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3.2.1. ATRA Titration 
In order to maximize the yield in cardiomyocytes, various doses of ATRA were 
administered daily to the differentiating cells. As mentioned, cardiac differentiation levels 
were evaluated by examining the expression of cardiac differentiation markers Myl2 and 
Tnnt2 at D5 under each ATRA treatment condition. Myl2 encodes a protein that wraps 
around the extension of the myosin heavy chains in the cell’s contractile system, and is 
necessary for contraction and thick filament stabilization (Moss & Fitzsimons, 2006; 
Rottbauer et al., 2006). Tnnt2 also encodes a protein which is an important part of the 
contractile system of cardiomyocytes, allowing myosin to bind the actin filament upon 
stimulation (Pereira et al., 2011). It is important to note that Tnnt2 can also be expressed 
in certain early stages of skeletal myoblast differentiation (Swiderski & Solursh, 1990). 
At D5 of H9c2 differentiation, the expression profile of Myl2 and Tnnt2 indicated that 
there was no statistically significant difference in cardiomyocyte yield with ATRA 
treatments of 10 nm and above (Figure 6). Daily administration of doses higher than 10 
nM, therefore, did not increase cardiomyocyte yield.  
Phase contrast microscopy showed that, when cells were only exposed to DM (no 
ATRA), by D5 most cells looked very elongated and many had fused together: indicating 
H9c2 skeletal muscle differentiation (Figure 7) (Comelli et al., 2011; Menard, 1999). This 
was expected since simple serum reduction should cause cells to transdifferentiate and 
adopt a skeletal muscle cell phenotype. With daily treatments of 10 nM or higher of 
ATRA, however, cells also looked elongated, but the majority had not fused together. 
Furthermore, most had round and easily visible nuclei, all characteristics of H9c2 cardiac 
differentiation (Brostrom et al., 2000; Menard, 1999). This suggested that cardiac 
differentiation had successfully been induced. However, at ATRA concentrations above 
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Figure 6. Cardiac differentiation marker expression following various doses of ATRA. RT-qPCR 
results showing the expression of cardiac differentiation markers Myosin light chain 2 (A) and Troponin T 
type 2 (cardiac) (B) in differentiating H9c2 cells treated daily with different concentrations of ATRA. Data 
shown are from one biological replicate, done in technical quadruplicate. Error bars represent standard error 
of the mean. Expression determined by the relative standard curve qPCR quantification method and 
normalized to Gapdh and Rsp12. Statistically significant differences determined by unpaired Student’s t-
test (GraphPad Prism 6 Software). * indicates p < 0.05. 
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Figure 7. Morphology of differentiating H9c2 cells treated daily with different concentrations of 
ATRA. Phase-contrast microscopy of H9c2 cells at (A) day zero (D0) differentiation, and (B) day five (D5) 
differentiation, after daily treatments of varying concentrations of ATRA. Images taken at 100X 
magnification. 
No ATRA 
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20 nM, by D5 fewer cells were adhering to the cell culture plate, suggesting that higher 
concentrations of ATRA were toxic. Therefore, 10 nM ATRA accompanied by serum 
reduction was used in this study to induce cardiac differentiation in H9c2 cells since it 
gave maximum cardiomyocyte yield with minimal toxicity. This treatment regime is 
consistent with the vast majority of current literature on H9c2 cells. 
 
3.2.2. Confirmation of lineage 
The progress of myocyte differentiation over time was examined next by phase 
contrast microscopy (Figure 8). As determined above, with only serum reduction (for 
skeletal muscle differentiation), cells became progressively longer and fused together, 
resulting in long, multinucleated myotubes  (Brostrom et al., 2000; Comelli et al., 2011; 
Menard, 1999). When serum reduction was accompanied by daily treatments of 10 nM 
ATRA, cells also became more elongated, but did not fuse together. Furthermore, their 
nuclei became rounder and more evident with phase-contrast microscopy (Brostrom et al., 
2000; Comelli et al., 2011; Menard, 1999). Therefore, microscopy results suggested the 
desired lineages had in fact been achieved in our time courses with the treatments 
described.  
The proportion of skeletal vs. cardiac muscle differentiation in a lineage was 
further evaluated by examining the mRNA expression of skeletal muscle differentiation 
marker Myog and cardiac differentiation marker Myl2, at day 6 (D6) of differentiation 
(Figure 9). Myog, a marker of skeletal muscle differentiation, is a transcription factor and 
one of four myogenic regulatory factors that are involved in the activation of skeletal 
myoblast differentiation (Edmondson & Olson, 1989; Kee et al., 2007; Sabourin & 
Rudnicki, 2001). The expression of these differentiation markers under both 
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B. Cardiac Differentiation (1% FBS and daily treatments of 10 nm ATRA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Verfication of lineage - Morphology of differentiating H9c2 cells. Morphology of H9c2 at D0, 
D4 and D7 of exposure to (A) serum reduced medium or, (B) serum reduced medium and daily treatments 
of 10 nM of ATRA. Images taken with phase-contrast microscopy at 100X magnification. 
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Figure 9. Verification of lineage - mRNA expression of differentiation markers. Lineage confirmation 
by examining the expression of skeletal muscle differentiation marker Myogenin (Myog), and cardiac 
differentiation marker myosin light chain 2 regulatory subunit (Myl2), at D6 differentiation. (-)ATRA 
indicates that these cells were only exposed to reduced serum medium, in an effort to induce skeletal 
muscle differentiation. (+)ATRA indicates that serum reduction was also accompanied by daily treatments 
of 10 nM ATRA in an effort to induce cardiac differentiation. Data represents RT-qPCR results from three 
biological replicates, done in technical quadruplicate. Results were analyzed by the relative standard curve 
quantification method and normalized to Gapdh and Rsp12. Error bars represent standard error of the mean. 
Statistically significant differences determined by unpaired Student’s t-test (GraphPad Prism 6 Software) 
with p < 0.05. 
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differentiation regimes showed that cells treated with ATRA and serum reduction had a 
statistically significant higher level of the cardiac differentiation marker Myl2 by D6 
differentiation. This confirmed that significantly higher levels of cardiac differentiation 
were achieved with ATRA treatments. Furthermore, cells subjected to serum withdrawal 
(but not treated with ATRA) had a statistically significant higher level of the skeletal 
muscle differentiation marker Myog at D6 differentiation. This in turn confirmed that 
skeletal muscle differentiation was successful, at least for a significant portion of this 
serum-deprived population. All in all, these results confirmed that we were successful in 
inducing myoblast differentiation into skeletal and cardiac muscle lineages. Therefore, 
mRNA and protein expression data for various genes could be confidently collected 
throughout differentiation and compared between lineages.  
 
3.3. Protein expression analysis 
Before analyzing the protein expression pattern of Rbm5 and Rbm10 during 
myoblast differentiation, it was essential to ensure that the correct bands being detected 
by Western blot analysis were used for protein expression quantification. Therefore 
transient overexpression experiments were performed in H9c2 cells during normal 
growth. RBM10v1, RBM10v2 and RBM5 were separately overexpressed and the 
resulting protein samples analyzed via Western Blot. We expected that when a specific 
Rbm protein’s cDNA was overexpressed, the corresponding band would increase in 
intensity compared to the control cells. 
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3.3.1. Rbm10 band identification 
For the detection of Rbm10, blots were probed with a commercially available 
rabbit anti-RBM10 (A301-006A) antibody from Bethyl Laboratories raised to residues 
880-930 (C-terminal region) of human RBM10 (100% homology with rat (accession 
number: P70501)) (Figure 1) (Amanchy et al., 2008; Wang et al., 2012). Both Rbm10v1 
and Rbm10v2 were expected to react with this antibody since they both only vary in the 
sequence of their N-terminal region. Western blots of protein extracts from cells 
overexpressing Rbm10v1 and Rbm10v2 enabled us to identify which band corresponded 
to each variant (Figure 10A): the approximately 135 kDa band corresponding to 
Rbm10v1, and the approximately 107 kDa band corresponding to Rbm10v2.  
 
3.3.2. Rbm5 band identification 
Western Blots of protein extracts from cells overexpressing RBM5 were first 
probed with a non-commercially available anti-RBM5 antibody, LUCA-15UK, which 
was raised to the first 15 N-terminal amino acids of the human RBM5 sequence (100% 
homology with rat [accession number: AAI66477]) (Figure 1). This antibody was used 
since it was well characterized and optimized (Fushimi et al., 2008; Mourtada-
Maarabouni et al., 2002; Rintala-Maki & Sutherland, 2004; Sutherland et al., 2000). 
LUCA-15UK detected two bands, only one of which, at approximately 113 kDa, 
increased in intensity when RBM5 was transiently overexpressed (Figure 10B). This 
indicated that the 113 kDa band corresponded to the full-length 25 exon Rbm5 transcript. 
Since this was the first time that this non-commercially available antibody had been used 
on rat protein sample, it was necessary to verify that these results were reproducible with 
another anti-RBM5 antibody. Therefore, a commercially available rabbit anti-RBM5 
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Figure 10. Rbm5 and Rbm10 Western blot band identification. A. Western blot results of protein from 
H9c2 cells transiently transfected with pcDNA3, pcDNA3.RBM10v1 or pcDNA3.RBM10v2 at 72 hours 
post-transfection. Blot probed with anti-Rbm10 antibody from Bethyl Laboratories, then stripped and 
probed for α-tubulin. B. Western blot results of protein from H9c2 cells transiently transfected with 
pcDNA3 or pcDNA3.RBM5 at 48 hours post-transfection. Blot probed for Rbm5 with non-commercially 
available LUCA-15UK antibody, then stripped and probed for α-tubulin. Following this, blot was probed 
for Rbm5 with Abcam antibody, stripped, and probed again for Rbm5 with SP1 antibody. Indicated ladder 
is in kDa. 
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antibody from Abcam (ab85504) was tested next. This second anti-RBM5 antibody was 
raised to the first 50 N-terminal amino acids of the human RBM5 sequence (100% 
homology with rat [accession number: AAI66477]) (Figure 1). Results with this Abcam 
antibody showed three distinct bands at approximately 92 kDa, 113 kDa and 140 kDa, 
respectively (Figure 10B). However, only the 113 kDa band increased in intensity when 
RBM5 was transiently overexpressed, which was consistent with the LUCA-15UK 
antibody results. This suggested that the upper and lower-most bands detected by the 
Abcam anti-RBM5 antibody were the result of non-specific interactions. Yet, the 
molecular mass of Rbm5 calculated from its amino acid content should be approximately 
92 kDa, the size of the lowest band detected by the anti-RBM5 Abcam antibody. 
Therefore, we used a third anti-RBM5 antibody raised to the whole RBM5 sequence in 
order to ensure that it was indeed the 113 kDa band that corresponded to Rbm5 (Figure 
1). This last anti-RBM5 antibody was a non-commercially available antibody, termed 
SP1, and was in fact raised to the recombinant purified full-length human RBM5 protein 
(Bonnal et al., 2008). The only band detected with the SP1 anti-RBM5 antibody, that was 
also consistent with those picked up by either the Abcam or LUCA-15UK anti-RBM5, 
was once again the 113 kDa band (Figure 10C). Furthermore, this was again the only 
band whose intensity increased when RBM5 was overexpressed. In summary, these 
results strongly suggested that the approximately 113 kDa band identified by all three 
anti-RBM5 antibodies corresponded to full-length Rbm5. For the following Western 
blots, only the Abcam anti-RBM5 antibody was used since it was commercially available. 
This antibody was also previously used in other Rbm5 studies (Li et al., 2012; Liang et 
al., 2012; Shao et al., 2012). 
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Using the optimal parameters determined in this chapter for gene expression 
quantification, cell culture and differentiation, and protein expression, the expression of 
Rbm5 and Rbm10 throughout H9c2 skeletal and cardiac myoblast differentiation could 
accurately be assessed. 
 
Chapter 4. Results – Rbm5 and Rbm10 Splice Variant Expression 
Throughout Rat Skeletal and Cardiac Myoblast Differentiation 
 
The results described in the previous chapter confirmed that we could commit 
myoblast cells to a specific lineage, and that mRNA and protein expression analysis 
techniques were optimized. Therefore, Rbm5 and Rbm10 splice variant mRNA and 
protein expression was examined throughout H9c2 skeletal and cardiac myoblast 
differentiation. It is important to note that we were particularly interested in significant 
changes in Rbm5 and Rbm10 expression that occurred within the first three days of 
differentiation, because this is when apoptosis and cell cycle arrest occur in 
differentiating cells. However, statistically significant changes in expression were 
evaluated throughout differentiation. At the mRNA level, differences of at least (+)2- or 
(-)0.5-fold were considered for statistical significance. In addition, we compared temporal 
expression of individual variants and isoforms between lineages (e.g., Rbm5 expression at 
D4 of skeletal and cardiac muscle differentiation). We also compared the expression 
levels of Rbm5 to Rbm10v1 in rat myoblasts to determine if their relative expression 
levels were the same as in transformed cells.  
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4.1. Rbm5 splice variant expression analysis 
The mRNA expression of three Rbm5 splice variants was investigated: Rbm5, 
Rbm5+5+6 and Lust (Figure 1). Sequences used for variant-specific primer design were 
based on known human RBM5 splice variant sequences since only full-length Rbm5 
mRNA had been reported in rat at that point. To date, the only Rbm5 transcript 
documented in rat remains full-length Rbm5.  
At the protein level, only full-length Rbm5 expression was investigated in this 
study since, even in human samples, a translational product has rarely been identified for 
RBM5+5+6 (Maquat & Carmichael, 2001; Sutherland et al., 2000) and not previously 
identified for Lust (Rintala-Maki & Sutherland, 2009). 
 
4.1.1. mRNA and protein expression of full-length Rbm5 did not correlate during 
myoblast differentiation 
First, RT-qPCR and Western blot analysis results showed that full-length Rbm5 
was expressed at the mRNA and protein levels in rat myoblasts and throughout their 
differentiation into skeletal and cardiac myocytes, respectively (Figure 11A, B and Figure 
12A-D). Surprisingly, during skeletal muscle differentiation, there were no statistically 
significant changes in Rbm5 mRNA expression between any two days of differentiation 
(Figure 11A). In fact, Rbm5 expression was very steady throughout the establishment of 
the skeletal muscle lineage, with expression values for each day of differentiation being 
very close to that at D0. These results, however, were not mirrored at the protein level 
(Figure 12E), which showed a gradual decline in Rbm5 from D2 to D7 of skeletal muscle 
differentiation.  
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Figure 11. Rbm5 mRNA splice variant expression throughout H9c2 skeletal and cardiac myoblast 
differentiation. RT-qPCR results for fold-change in expression of various Rbm5 splice variants from D0 
through D7 of H9c2 skeletal and cardiac myoblast differentiation. Figures A, C and E show the various 
Rbm5 splice variants’ expression throughout skeletal myoblast differentiation, whereas B, D and F show 
their expression throughout cardiac differentiation. mRNA expression analyzed by the comparative Ct 
qPCR quantification method and expressed as fold-change in expression from D0 differentiation. Values 
normalized to Gapdh. Statistically significant differences were evaluated between two days of 
differentiation with fold-changes at least greater than 2 or less than 0.5 with a Student’s unpaired t-test (* 
indicates p < 0.05, ** indicates p < 0.01). Data represent results from biological triplicates, performed in 
technical quadruplicate. Error bars represent standard error. 
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Figure 12. Rbm5 protein expression throughout H9c2 skeletal and cardiac myoblast differentiation. 
A - D. Western blots of H9c2 skeletal (A, C) and cardiac myoblast differentiation (B, D) protein samples, 
from D0 to D7 of differentiation, probed with anti-Rbm5 Abcam antibody. Following Rbm5 exposure, blots 
were stripped and probed for α-tubulin (used to normalize results). Blots are results from biological 
duplicates, and represent results for technical duplicates performed for each biological replicate. E and F. 
Quantification of Western blot results for Rbm5 expression throughout H9c2 skeletal and cardiac myoblast 
differentiation, respectively. Blots were probed with anti-Rbm5 antibody from Abcam, then stripped and 
probed for α-tubulin, which was used to normalize. Densitometry was carried out to quantify expression. 
Results are shown as fold-change in expression from D0 differentiation, and represent data from biological 
duplicates, performed in technical duplicates. Error bars represent standard error. Statistically significant 
differences were only evaluated between two days of differentiation with fold-changes at least greater than 
2 or less than 0.5 with a Student’s unpaired t-test (* indicate p < 0.05). Indicator of statistical significance 
placed directly above a bar refers to a statistically significant difference with the D0 value.
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Throughout cardiac differentiation, Rbm5 mRNA expression only changed 
significantly at D4 differentiation, when it decreased compared to D0 (Figure 11B). 
Overall, the trend of Rbm5 mRNA expression during cardiac differentiation revealed a 
non-statistically significant drop in Rbm5 expression soon after induction of 
differentiation, and quite low expression levels sustained throughout the establishment of 
the lineage. However, again in opposition to the mRNA data, protein levels of Rbm5 
were very stable throughout cardiac differentiation, and always close to that at D0 (Figure 
12F).  
Comparison of full-length Rbm5 expression patterns between skeletal and cardiac 
myoblast differentiation showed similar results in the sense that in both lineages, only 
Rbm5 mRNA or protein expression changed. During skeletal muscle differentiation, it 
was Rbm5 protein expression that gradually decreased, with mRNA levels remaining 
steady. In opposition, during cardiac differentiation, it was Rbm5 mRNA expression that 
decreased, while its protein expression remained constant. Therefore, during the 
establishment of both lineages only Rbm5 mRNA or protein expression decreased, while 
Rbm5 expression at the other level stayed constant.  
 
4.1.2. Rbm5+5+6 mRNA expression varied significantly throughout both skeletal and 
cardiac myoblast differentiation 
The second Rbm5 splice variant studied from D0 to D7 of rat skeletal and cardiac 
myoblast differentiation was Rbm5+5+6. First, RT-qPCR results showed that Rbm5+5+6 
was expressed in rat myoblasts and throughout their differentiation into both skeletal and 
cardiac myocytes, respectively (Figure 11C, D). Within the skeletal muscle lineage, 
Rbm5+5+6 expression showed a statistically significant difference only between D1 and 
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D6 of differentiation (D1<D6) (Figure 11C). Nonetheless, Rbm5+5+6 expression did 
vary throughout skeletal muscle differentiation, with expression decreasing slightly 
during the first few days of differentiation, increasing around D5, and decreasing again by 
D7.  
During cardiac differentiation, however, this peak in expression at D5 of 
differentiation was not seen, at least not to the degree at which it occurred during skeletal 
muscle differentiation. Rather, throughout cardiac differentiation Rbm5+5+6 expression 
was decreased immediately following induction of differentiation and stayed quite low 
until D7 (statistically significant decreases in expression occurred at D2, D3 and D7 of 
differentiation, compared to D0) (Figure 11D). Therefore, overall Rbm5+5+6 expression 
was higher during skeletal muscle differentiation, compared to cardiac. Thus, Rbm5+5+6 
mRNA expression varied more and was generally higher during skeletal muscle 
differentiation, than during cardiac differentiation. 
 
4.1.3. Lust expression only varied significantly during skeletal muscle differentiation 
The last Rbm5 splice variant which was analyzed in this study was Lust. RT-qPCR 
results showed that Lust was also expressed in rat myoblasts and throughout rat skeletal 
and cardiac myoblast differentiation (Figure 11E, F). Throughout the establishment of the 
skeletal muscle lineage, significant changes in Lust expression were observed at D3 and 
D7 of differentiation, when Lust expression significantly dropped compared to D2 (Figure 
11E). The general trend of Lust expression throughout skeletal muscle differentiation 
showed that it varied, with slightly higher expression levels being seen around D2 and 
D5, and lower levels detected on the days in between. Different results were obtained 
when Lust expression was examined during cardiac differentiation: Lust mRNA levels 
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remained close to that at D0 and did not change significantly between any two days of 
differentiation (Figure 11F). 
 
4.1.4. Lust mRNA expression was lower than that of full-length Rbm5 and Rbm5+5+6 in 
rat myoblasts 
Raw qPCR results (Ct values) from D0 of differentiation for all Rbm5 splice 
variants studied were compared in order to determine their relative expression in rat 
myoblasts. The Ct values of Rbm5 and Rbm5+5+6 were quite similar; however those for 
Lust were approximately 2.5 cycles higher (Table 2). This indicated that Lust mRNA 
expression was lower than that of full-length Rbm5 and Rbm5+5+6 in rat myoblasts (Ct 
values and expression levels are inversely correlated). It is important to note that although 
different primer pairs were used to quantify the expression of the various Rbm5 splice 
variants, primer pair efficiencies were quite similar and all above 1.9 . Therefore, the 
variation in primer efficiencies should not account for the large difference in Ct values 
seen between Lust and the other Rbm5 splice variants studied. 
 
4.1.5. Rbm5 splice variants had different expression patterns throughout differentiation 
Comparison of Rbm5 splice variant mRNA expression profiles first showed that 
the expression of Rbm5+5+6 and Lust changed throughout skeletal muscle differentiation 
and that their corresponding expression patterns were very similar (Figure 11C, E). 
However, full-length Rbm5 mRNA expression was stable throughout skeletal muscle 
differentiation (Figure 11A). On the other hand, throughout cardiac differentiation, it was 
the expression of full-length Rbm5 and Rbm5+5+6 that changed and which showed 
similar expression patterns (Figure 11B, D). Therefore, only Rbm5+5+6 mRNA 
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Rbm5 splice variants 
 Splice variant 
primer efficiency 
Average splice 
variant Ct 
Average Gapdh Ct Average delta Ct 
(Ctsplice variant– CtGapdh) 
Rbm5 1.95 24.494 ± 0.454 17.768 ± 0.526 6.726 ± 0.553 
Rbm5+5+6 1.99 24.926 ± 0.432 18.069 ± 0.440 6.858 ± 0.638 
Lust 1.94 27.628 ± 0.763 18.065 ± 0.440 9.563 ± 0.701 
Rbm10 splice variants 
 Splice variant 
primer efficiency 
Average splice 
variant Ct 
Average Gapdh Ct Average delta Ct 
(CtRbm10v1– CtGapdh) 
Rbm10v1 2.00 27.393 ± 0.451 17.768 ± 0.526 9.625 ± 0.560 
 
Table 2. Raw qPCR data for Rbm5 and Rbm10 splice variant expression at D0 differentiation.         
Values represent the average Ct value for the variant in question from D0 skeletal and cardiac myoblast 
differentiation mRNA samples performed in biological triplicate and technical duplicate for each lineage. 
Values are shown as ± standard error. Gapdh was used to normalize. Splice variant primer efficiency 
calculated as shown in Figure 3. 
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expression changed significantly throughout both skeletal and cardiac muscle 
differentiation, whereas Rbm5 mRNA expression changed only during cardiac 
differentiation and Lust during skeletal muscle differentiation. 
 
4.2. Rbm10 splice variant expression analysis 
Expression of the two most highly expressed Rbm10 variants, Rbm10v1 and 
Rbm10v2, was examined. Sequences used for variant-specific primer design were from 
documented rat Rbm10 splice variant sequence data available at the time of primer 
design, as described in Chapter 1. It is important to note that since we designed these 
primers, the exon numbering for rat Rbm10 has been changed to match the human 
RBM10 mRNA (exon numbering was previously offset by two between rat and human 
Rbm10). Rbm10v1 mRNA expression levels were measured using RT-qPCR. End point 
(RT-PCR) was used to evaluate Rbm10v2 mRNA expression, since primers that spanned 
the spliced exon would not specifically amplify Rbm10v2. 
 
4.2.1. Rbm10v1 expression varied only during skeletal muscle differentiation, and only at 
the protein level  
RT-qPCR and Western blot results for Rbm10v1 expression first showed that this 
Rbm10 variant was in fact expressed in rat myoblasts and throughout rat skeletal and 
cardiac myoblast differentiation (Figure 13C, D and Figure 14A-D). At the mRNA level, 
Rbm10v1 expression did not change significantly between any two days of skeletal 
muscle differentiation, and did not significantly vary throughout the establishment of the 
lineage (Figure 13C). At the protein level, however, Rbm10v1 expression slowly 
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Figure 13. Rbm10 splice variant expression throughout H9c2 skeletal and cardiac myoblast 
differentiation. A and B. Raw RT-PCR data for Rbm10v1 and Rbm10v2 expression throughout rat skeletal 
(A) and cardiac myoblast differentiation (B), respectively. Results are representative of results from 
biological triplicates, performed in technical duplicate. Gapdh was used as reference gene and the ladder is 
a 100bp ladder.  C and D. RT-qPCR results for expression of Rbm10v1 from D0 to D7 of H9c2 skeletal (C) 
and cardiac (D) myoblast differentiation. mRNA expression was analysed by the comparative Ct qPCR 
quantification method. E and F. RT-PCR results for Rbm10v2 expression from D0 to D7 of H9c2 skeletal 
(E) and cardiac (F) myoblast differentiation. mRNA expression was determined by electrophoresing PCR 
products on a 2% TAE Agarose Gel, and densitometry was carried out. All expression values were graphed 
as fold-change in expression from D0 differentiation. Values were normalized to Gapdh. Statistically 
significant differences were evaluated between two days of differentiation with fold-changes at least greater 
than 2 or less than 0.5 with a Student’s unpaired t-test (** indicates p < 0.01). Data represent results from 
biological triplicates, performed in technical duplicates. Error bars represent standard error. 
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Figure 14. Rbm10v1 and Rbm10v2 protein expression throughout H9c2 skeletal and cardiac 
myoblast differentiation. A - D. Western blots of H9c2 skeletal (A, C) and cardiac (B, D) myoblast 
differentiation protein samples, from D0 to D7 of differentiation, probed with anti-Rbm10 Bethyl antibody. 
Following, blots were stripped and probed for α-tubulin (used to normalize results). Blots are from 
biological duplicates, and representative of technical duplicates performed for each biological replicate. E - 
H. Quantification of Western blot results for Rbm10 expression throughout H9c2 skeletal and cardiac 
myoblast differentiation, respectively (normalized to α-tubulin). Densitometry was carried out to quantify 
expression. Results are shown as fold-change in expression from D0 differentiation, and represent data from 
biological duplicates, performed in technical duplicates. Error bars represent standard error. Statistically 
significant differences were only evaluated between two days of differentiation with fold-changes at least 
greater than two or less than 0.5 with a Student’s unpaired t-test (* indicates p < 0.05, and ** indicates p < 
0.01). Indicator of statistical significance placed directly above a bar refers to a statistically significant 
different with the D0 value (black indicator), D1 value (grey indicator), or D2 (light grey indicator). 
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decreased, with significantly lower levels being seen at D6 and D7 of skeletal muscle 
differentiation, compared to D0 (Figure 13E).  
During cardiac differentiation, Rbm10v1 mRNA expression also showed no 
statistically significant change (Figure 13D). Rbm10v1 protein expression during cardiac 
differentiation was consistent with these mRNA results (Figure 14F). In sum, only during 
skeletal muscle differentiation, and at the protein level, did Rbm10v1 expression change 
significantly.  
 
4.2.2. Rbm10v2 expression varied most significantly at the protein level throughout both 
skeletal and cardiac myoblast differentiation 
RT-PCR and Western blot results showed that Rbm10v2 is expressed in rat 
myoblasts and throughout their differentiation into skeletal and cardiac myocytes, 
respectively (Figure 13A, B and Figure 14G, H). At the mRNA level, Rbm10v2 
expression gradually decreased throughout skeletal muscle differentiation, with a 
statistically significant drop in expression achieved by D5, compared to D0 (Figure 13E). 
At the protein level, a decrease in Rbm10v2 expression was also seen throughout skeletal 
muscle differentiation. However, a statistically significant drop was seen much earlier 
than at the mRNA level: Rbm10v2 protein expression was statistically significantly 
decreased as soon as D3 of differentiation, while mRNA expression was only 
significantly decreased by D5 (Figure 14G).  
In regards to Rbm10v2 expression during cardiac differentiation, no statistically 
significant changes in expression were seen at the mRNA level. At the protein level 
though, a significant decrease was seen at D1, D5, D6 and D7, compared to D0 (Figure 
14H). Therefore, during skeletal muscle differentiation both Rbm10v2 mRNA and protein 
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expression were significantly decreased near the end of differentiation, with particularly 
significant decreases occurring as of D3 at the protein level. During cardiac 
differentiation, however, only Rbm10v2 protein expression changed significantly, and 
only by D5.  
 
4.2.3. Rbm10v2 was more highly expressed than Rbm10v1 in myoblasts, and throughout 
differentiation 
Raw RT-PCR results for Rbm10 expression showed that Rbm10v2 was much 
more highly expressed than Rbm10v1 in rat myoblasts, and throughout their 
differentiation into skeletal and cardiac myocytes (Figure 13A, B). This was also true at 
the protein level, with the difference being even more pronounced during skeletal muscle 
differentiation, compared to cardiac (Figure 14A-D). In fact, Rbm10v2 protein expression 
was almost always twice that of Rbm10v1 throughout a large part of skeletal muscle 
differentiation (Figure 15A).  
It is important to note that the same RT-PCR primer pair was used to evaluate 
Rbm10v1 and Rbm10v2 mRNA expression in this part of the analysis (the primer pair 
corresponded to sequences within the exons on each side of the spliced exon, and thus 
both variants were detected in the same PCR reaction). Therefore, the difference in 
expression observed between Rbm10v1 and Rbm10v2 could not be simply due to a 
difference in primer pair efficiencies. Furthermore, at the protein level, Rbm10 expression 
was evaluated using the Bethyl anti-Rbm10 antibody described in Chapter 2, which was 
raised to the C’-terminus of Rbm10. Since the exon which differentiates Rbm10v1 and 
Rbm10v2 is in the N’-terminal region of the protein, both variants contained the entire 
sequence to which the antibody was raised. Therefore, Rbm10v1 and Rbm10v2 should be 
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Figure 15. Ratio of Rbm10v2/Rbm10v1 protein expression throughout H9c2 skeletal and cardiac 
myoblast differentiation. A, B. Ratio of Rbm10v2/Rbm10v1 protein expression resulting from 
quantification of Western blot results for Rbm10 expression throughout H9c2 skeletal and cardiac myoblast 
differentiation, respectively. Blots were probed with Bethyl anti-Rbm10 antibody, and densitometry was 
carried out. Results represent data from biological duplicates, performed in technical duplicates. Error bars 
represent standard error.  
A B 
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detected by the antibody with approximately the same affinity. In sum, Rbm10v2 mRNA 
and protein expression was greater than that of Rbm10v1 in rat myoblasts and throughout 
their differentiation into both skeletal and cardiac myocytes. Also, during skeletal muscle 
differentiation, these differences in expression were more pronounced. 
 
4.2.4. Rbm10v1 mRNA expression was lower than that of Rbm5 in myoblasts 
Comparison of Ct values for Rbm10v1 and the various Rbm5 splice variants 
studied revealed that Rbm10v1 expression levels in rat myoblasts were lower than that of 
Rbm5 and Rbm5+5+6, and close to that of Lust (Ct values and expression levels are 
inversely proportional) (Table 2). It is important to note that different primer pairs were 
used to amplify Rbm10v1 and the various Rbm5 splice variants. Therefore, some of the 
observed variations in expression could be due to differences in primer efficiencies. 
However, in this case, all primer efficiencies were very close (all within 0.06 of each 
other), and the expression differences were quite large. Hence, differences in primer pair 
efficiencies alone are not likely to be the cause of the important expression differences 
seen between Rbm10v1 and Rbm5 in rat myoblasts. Due to the lack of specificity of qPCR 
primers for Rbm10v2, it was not possible to directly compare the expression of Rbm10v2 
to that of Rbm5 and Rbm5+5+6 in rat myoblasts. However, based on RT-PCR and 
Western blot results, we had determined that Rbm10v2 expression was at least higher than 
that of Rbm10v1 in rat myoblasts, and thus closer to that of Rbm5 and Rbm5+5+6. 
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Chapter 5. Discussion 
RNA-binding proteins can influence various cellular processes due to the 
important role they play in many co- and post-transcriptional events. Two such RNA 
binding proteins, RBM5 and RBM10, have been studied quite heavily in transformed 
cells. However, much remains to be elucidated concerning their exact mechanism of 
action, and whether their associated roles in transformed cells are the same as in non-
transformed systems. As a first step in determining if these RNA binding proteins play a 
role in non-transformed cells, and to gain a hint as to what this role may be, Rbm5 and 
Rbm10 expression was examined throughout rat skeletal and cardiac myoblast 
differentiation. The myoblast differentiation model is a particularly useful model in which 
to study Rbm5 and Rbm10 since, as described in Chapter one, Rbm5 and Rbm10 are both 
highly expressed in mature human skeletal and cardiac muscle cells (Figure 2). 
Furthermore, cellular processes in which Rbm5 and Rbm10 have been associated in 
transformed cells are also important to myoblast differentiation, particularly cell cycle 
arrest, apoptosis and alternative splicing. These three cellular events occur at specific 
times during myoblast differentiation. For instance, cell cycle arrest occurs approximately 
two days following induction of myogenic differentiation (Andrés & Walsh, 1996; 
Novitch et al., 1999; Walsh & Perlman, 1997), similar to what is seen during cardiac 
differentiation (Ahuja et al., 2007; Poolman et al., 1998). Apoptosis levels in 
differentiating cells also reach a maximum after approximately two days in DM (Dee et 
al., 2002; Sandri et al., 1996). Finally, alternative splicing occurs throughout 
differentiation, with various factors being alternatively spliced at specific times 
throughout this process (Bland et al., 2010; Revil et al., 2010). Therefore, if Rbm5 and 
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Rbm10 are involved in the same cellular processes in transformed and non-transformed 
systems, we would expect their expression to change when these events occur in 
differentiating cells.  
 
5.1. Rbm5 and Rbm10 splice variants are expressed in rat myoblasts 
First, we found that all examined Rbm5 and Rbm10 splice variants were in fact 
expressed in rat myoblasts, as revealed by PCR or qPCR amplification of the mRNA 
encoding the specific splice variants, or the detection of specific protein isoforms by 
Western blot. This is the first report of Rbm5+5+6 and Lust mRNA expression in rat 
tissue, in myoblasts, and throughout skeletal and cardiac myoblast differentiation. Also, 
this is the first report of Rbm5, Rbm10v1 and Rbm10v2 mRNA and protein expression in 
rat muscle cells, and throughout rat skeletal and cardiac myoblast differentiation. Thus, 
this study not only gives a first idea as to whether Rbm5 and Rbm10 splice variants play a 
role in non-transformed systems, but is the first to describe their expression in rat muscle 
cells. 
 
5.2. Rbm5 and Rbm10 splice variants are not expressed at the same level in rat 
myoblasts 
 
5.2.1. In myoblasts, as in transformed cells, Lust expression is lower than that of Rbm5  
Based on Ct values for Rbm5, Rbm5+5+6 and Lust at D0 of differentiation, it was 
possible to conclude that the expression of Lust was much lower than that of the other two 
Rbm5 variants in rat myoblasts (Table 2). Lower levels of Lust, compared to Rbm5, have 
also been previously reported in human heart and skeletal muscle tissues, as well as in a 
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wide range of other lymphoid and non-lymphoid tissues, including the brain and pancreas 
(Sutherland et al., 2000). This has also been reported in transformed systems, including 
Hela (cervical cancer cells), A549 (adenocarcinomic alveolar basal epithelial cells) and 
SW480 (colon adenocarcinoma cells) cell lines (Sutherland et al., 2000). The consistency 
in the relative expression levels of Lust and Rbm5 throughout these various transformed 
and non-transformed systems is another hint that these Rbm5 variants may play a similar 
role in all of these cell types. 
 
5.2.2. Unlike in transformed cells, Rbm10v2 expression is higher than that of Rbm10v1 in 
rat myoblasts and throughout myoblast differentiation 
In rat myoblasts, and throughout their differentiation into skeletal and cardiac 
myocytes, respectively, Rbm10v2 expression was shown to be consistently higher than 
that of Rbm10v1. These results were observed at both the mRNA and protein levels 
(Figure 13A-D and Figure 15). However, previous reports investigating RBM10 
expression in transformed cells have shown Rbm10v1 expression to be higher than that of 
Rbm10v2. For instance, in Jurkat cells, RT-PCR results showed much higher expression 
levels for Rbm10v1 compared to Rbm10v2 (Wang et al., 2012). These opposing results 
suggest that Rbm10v2 may have a particularly important role in myoblasts, and perhaps 
throughout differentiation, thus explaining its increased expression compared to 
Rbm10v1. Alternatively, these results could also suggest that Rbm10v1 is necessarily 
down-regulated or less highly expressed in these non-transformed cells (assuming 
Rbm10v1 does indeed influence such functions in myoblast, like it has been shown to do 
in transformed cells). 
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5.3. Possible functions of Rbm5 and Rbm10 splice variants in myoblast 
differentiation 
Based on the temporal expression of Rbm5 and Rbm10 throughout differentiation, 
and comparison of their expression patterns between lineages, it was possible to 
determine possible functions with which Rbm5 and Rbm10 splice variants may be 
associated during differentiation. 
 
5.3.1. Rbm5 may be involved in apoptosis and cell cycle arrest  
The analysis of the protein expression profiles showed that during skeletal muscle 
differentiation, the expression of Rbm5 began decreasing at D3 of differentiation, and 
continued to drop for the remainder of the differentiation period studied (Figure 12E). 
The timing of this drop in expression suggests that Rbm5 may be involved in cellular 
events which occur during the first two days of differentiation, before this decrease in 
expression is observed. Such events could include apoptosis and cell cycle arrest (Figure 
2). As described in Chapter one, Rbm5 has indeed been shown to modulate apoptosis and 
cell cycle arrest in transformed cells; therefore Rbm5 could also play such a role in non-
transformed system. It is important to note that no such drop in Rbm5 protein expression 
was observed during cardiac differentiation (Figure 12F). Hence, Rbm5 may be involved 
in skeletal muscle differentiation-specific apoptosis and cell cycle arrest events. For 
example, Rbm5 may be involved in the terminal cell cycle arrest which occurs at 
approximately D2 of only skeletal muscle differentiation (cell cycle withdrawal is not 
permanent during cardiac myoblast differentiation). This potential role for Rbm5 in 
skeletal muscle differentiation could be further investigated by determining how/if the 
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expression of cell cycle regulatory factors vary when Rbm5 expression levels are altered 
in differentiating skeletal myoblasts.  
 
5.3.2. Rbm5+5+6 and Lust may regulate similar cellular events, or each other, 
throughout skeletal myoblast differentiation 
Rbm5+5+6 and Lust mRNA expression profiles were very similar throughout 
skeletal myoblast differentiation. Notably, both showed an increase in expression at D2 
and D5 of differentiation (Figure 11C, D). This coordinated expression during skeletal 
muscle differentiation may hint at the role of Rbm5+5+6 and Lust in this process. For 
instance, the increase in expression at D2 could indicate their involvement in cell cycle 
arrest and/or apoptosis, since it is around this time that these events occur in 
differentiating cells (Figure 2). This possibility could be tested by overexpressing 
Rbm5+5+6 and/or Lust in myoblasts and during the first days of skeletal muscle 
differentiation, and examining the effect on the expression of cell cycle arrest and 
apoptosis markers, such as p21 and poly(ADP ribose) polymerase (Parp), respectively. 
An increase in Rbm5+5+6 and Lust expression was also observed at D5, which 
could indicate their involvement in the alternative splicing of metabolic or structural 
proteins important to skeletal muscle differentiation, since the expression of such factors 
begins at approximately this point in differentiation. To further investigate this potential 
role, levels of Rbm5+5+6 and Lust could once again be modified in myoblasts, and 
changes in the alternative splicing of important metabolic and structural proteins 
evaluated via RT-qPCR.  
In transformed cells Rbm5+5+6 and Lust have been shown to have opposing 
effects in regards to their role in cell cycle arrest and apoptosis. For instance, 
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overexpression of RBM5+5+6t cDNA (a truncated form of RBM5+5+6) in transformed 
cells inhibited proliferation and sensitized cells to apoptosis mediated by cell surface 
receptor CD95 (Sutherland et al., 2000). On the other hand, overexpression of Je2 (a 
partial LUST sequence) has been shown to suppress various types of apoptosis, including 
CD95-mediated apoptosis (Mourtada-Maarabouni et al., 2002; Sutherland et al., 2000). 
Therefore, another possible explanation for the correlation between Rbm5+5+6 and Lust 
expression throughout skeletal muscle differentiation could be that they are regulating 
each other’s expression. For example, Lust expression may mirror that of Rbm5+5+6 in 
order to prevent excessive cell cycle arrest or apoptosis in differentiating cells. Or, 
Rbm5+5+6 expression may mirror that of Lust in order to ensure that differentiating cells 
do undergo cell cycle arrest at the right time following induction of skeletal muscle 
differentiation. This assumes that Rbm5+5+6 and Lust play similar roles in both 
transformed and non-transformed systems, and thus that these roles are antagonistic. In 
order to evaluate this possibility, future experiments could involve examining the 
expression of skeletal muscle differentiation-specific cell cycle arrest markers upon 
Rbm5+5+6 and Lust overexpression, respectively, in rat myoblasts: if both Rbm5+5+6 
and Lust alter the expression of these markers in different ways, it could further suggest 
that Rbm5+5+6 and Lust’s roles in differentiation are antagonistic. In sum, Rbm5+5+6 
and Lust may both play a similar role in the events of early skeletal myoblast 
differentiation, including apoptosis and/or cell cycle arrest. Alternatively, their roles in 
differentiation may be opposite, as in transformed cells, thus, Rbm5+5+6 and Lust may 
regulate each other’s expression during skeletal muscle differentiation in order to ensure 
that the establishment of the skeletal muscle cell lineage is successful. 
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5.3.3. Lust expression, and/or a decrease in Rbm5+5+6 expression may be important to 
the establishment of the cardiac lineage 
In contrast to what was observed throughout skeletal muscle differentiation, the 
expression patterns for Rbm5+5+6 and Lust did not correlate during cardiac 
differentiation: Rbm5+5+6 mRNA expression decreased and remained low as of D1 
differentiation (Figure 11D), while Lust mRNA levels remained constant (Figure 11F). It 
is important to note that, in transformed cells, Lust has been shown to influence 
Rbm5+5+6 expression. In fact, Lust has been shown to upregulate Rbm5+5+6 
expression, and down regulate Rbm5+5+6t (Rintala-Maki & Sutherland, 2009). 
Therefore, the observed Rbm5+5+6 and Lust expression profiles during cardiac 
differentiation could suggest that (a) Lust expression is consistent during cardiac 
differentiation since down-regulation of Rbm5+5+6(t) is necessary for the establishment 
of the cardiac lineage, and/or (b) Lust expression itself is important for establishing the 
cardiac lineage. In the first possibility, Rbm5+5+6 may necessarily be down-regulated in 
cardiac myoblast differentiation in order to ensure that differentiating cells are not targets 
for apoptosis, even though they do not undergo irreversible cell cycle. This hypothesis 
assumes that Rbm5+5+6 can sensitize non-transformed cells to apoptosis, as it has been 
shown to do in transformed cells. This possibility could be further evaluated by 
overexpressing Rbm5+5+6 in myoblasts and determining its effect on apoptosis (by 
examining the expression of apoptosis markers such as Parp), and cell number and 
viability (using a CASY counter for example). The second possibility is that Lust 
expression is important to cardiac differentiation. This could be the case if Lust plays a 
general role in regulating the expression and/or alternative splicing of cardiac-specific 
differentiation factors. To test this alternate hypothesis, Lust could be overexpressed in 
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myoblasts, and the expression and/or alternative splicing of cardiac-specific 
differentiation factors, such as Tnnt2, evaluated by RT-qPCR and/or Western Blot (may 
be hard to knockdown only the Lust Rbm5 transcript, therefore overexpression 
experiments would be a good starting point). Thus, Rbm5+5+6 and Lust also seem to 
play an important, and potentially antagonistic, role in cardiac differentiation. 
 
5.3.4. Rbm10v1 and Rbm10v2 may also be involved in apoptosis and cell cycle arrest 
events which are specific to skeletal muscle differentiation 
Like Rbm5, Rbm10v1 and Rbm10v2 protein expression varied significantly 
during skeletal muscle differentiation, dropping around D2, and remaining low until D7 
(Figure 14E, G).  Since cell cycle arrest and apoptosis occur at their maximum during the 
first few days of differentiation (Figure 2), when Rbm10v1 and Rbm10v2 expression is 
high, it suggests that both variants may play a role in these cellular processes. This would 
be consistent with what has been previously documented regarding the role of Rbm10v1 
and Rbm10v2 in transformed cells, and could be evaluated by altering levels of Rbm10v1 
and Rbm10v2 in rat myoblasts and throughout differentiation, and evaluating the 
consequent changes in expression of cell cycle arrest and apoptosis markers (i.e. p21 and 
Parp). During cardiac differentiation, however, similar variations in Rbm10v1 and 
Rbm10v2 protein expression were not observed. This suggests that the role of these 
Rbm10 variants in apoptosis, cell cycle arrest and/or other cellular processes may be 
specific to skeletal muscle differentiation. Thus, for instance, they may be involved in the 
terminal cell cycle arrest which is specific to the skeletal muscle lineage.  
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5.3.5. Rbm10v2 may be an important regulator of alternative splicing during cardiac 
differentiation 
The protein expression profile for Rbm10v2 throughout cardiac differentiation 
shows that its expression fell very soon following induction of differentiation, increased 
near D3, and then dropped until D7. This is a different pattern than that seen throughout 
skeletal muscle differentiation, and suggests a different function for this Rbm10 variant in 
both lineages. At D3 of cardiac differentiation, when Rbm10v2 expression was shown to 
be increased, cell cycle arrest and apoptosis have already occurred in differentiating cells 
(Figure 2). However, the expression of specific metabolic proteins required for the 
establishment of the target muscle cell type begins (Andrés & Walsh, 1996). Therefore, 
Rbm10v2 may be involved in regulating the expression and/or the alternative splicing of 
such metabolic factors. Such a function has not yet been reported for Rbm10v2. However, 
in transformed cells, knockdown of Rbm10 has been shown to affect the expression and 
alternative splicing of many different genes (manuscript in preparation). Hence, although 
its role may be different, Rbm10v2 appears to be important to both skeletal and cardiac 
muscle cell differentiation. 
 
5.4. Rbm5, Rbm10v1 and Rbm10v2 may be post-transcriptionally regulated 
The mRNA and protein expression profiles rarely correlated in this study, with the 
most significant variations in expression usually only seen at the protein level. This held 
true, at least to a certain extent, for Rbm5, Rbm10v1 and Rbm10v2 expression throughout 
both skeletal and cardiac myoblast differentiation. The lack of correlation between 
mRNA and protein expression levels suggests that Rbm5, Rbm10v1 and Rbm10v2 may be 
the targets of post-transcriptional or translational regulation throughout differentiation. 
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One reason why these variants may be regulated in such a way during differentiation is 
that the effects of post-transcriptional and translational regulation are experienced much 
faster in the cell than the modulation brought about by transcriptional regulation. Thus the 
cell can more rapidly respond to environmental variations (i.e. exposure to differentiation 
medium) (Holcik & Sonenberg, 2005). During differentiation there are many cellular 
events occurring at once and in tandem, with each being strictly regulated by specific 
mechanisms. Therefore, immediate changes in the expression levels of particular proteins 
(perhaps including Rbm5, Rbm10v1 and Rbm10v2) could be necessary, and thus 
accomplished via post-transcriptional or translational modifications (Yahi et al., 2006).   
An example of a protein which undergoes post-translational regulation during 
differentiation is the transcription factor Myocyte enhancer factor 2 (MEF2). During 
differentiation, MEF2 is acetylated, allowing it to bind better to DNA and thus increasing 
the transcription of its target genes (Angelelli et al., 2008). Another example of post-
translational regulation in muscle is that of FoxO3, a member of the Forkhead Box O 
(FoxO) family of transcription factors. FoxO3 regulates the expression of various muscle 
atrophy related genes (Bertaggia et al., 2012; Mammucari et al., 2007; Sandri et al., 
2004), and can also be acetylated. FoxO3 acetylation leads to a decrease in its activity, 
and consequent relocation to the cytoplasm. Once in the cytoplasm, FoxO3 is 
ubiquitylated by a ubiquitin ligase and consequently degraded (Bertaggia et al., 2012; 
Brault et al., 2010). This mechanism is extremely important in the prevention of excessive 
muscle mass loss, for example (Bertaggia et al., 2012). Therefore, the post-transcriptional 
and/or translational regulation of Rbm5, Rbm10v1 and Rbm10v2 suggested in the current 
study hint to the importance of their controlled expression in development. Based on their 
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amino acid sequences, such modifications could include phosphorylation and/or 
acetylation. 
 
5.5. Absence of expression change does not necessarily indicate absence of function  
One important point to remember when interpreting the results of this study is that 
samples were collected only once every 24 hours throughout the first seven days of 
myoblast differentiation. Therefore, a dramatic peak or drop in the expression of an Rbm5 
or Rbm10 variant could have been missed. For example, TNF-alpha was shown to have 
an important peak in expression within the first 24 hours of C2C12 skeletal myoblast 
differentiation (Li & Schwartz, 2001). Such a rapid change in expression would not have 
been detected in our study. Thus, future work could include taking more samples, 
especially throughout the first 48 to 72 hours of differentiation, when apoptosis and cell 
cycle arrest occur, to see if such dramatic and rapid shifts in Rbm5 or Rbm10 splice 
variant expression occur.  
Furthermore, when interpreting these results it is important to remember that if a 
variant does not undergo significant changes in expression throughout differentiation, this 
does not necessarily mean that the variant is not playing a role. For example, the 
expression of RBM4 was shown not to change significantly during differentiation. 
However, it was suggested that Rbm4 may still play an important role in differentiation, 
by strategically down-regulating polypyrimidine tract-binding (PTB) protein. PTB is a 
very important regulator of alternative splicing and other aspects of mRNA metabolism in 
mammalian cells (Lin & Tarn, 2011; Sawicka et al., 2008). Therefore, this work is only a 
first step in determining if Rbm5 and Rbm10 play a role in myoblast differentiation, and 
what that role may be. 
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5.6. Conclusion 
 
RBM5 and RBM10 play an important role in transformed cells, in part by 
affecting the alternative splicing and/or expression of factors involved in apoptosis and 
cell cycle arrest, two processes that, if gone array, can lead to the development of cancer 
(Reed, 1999). Little is known, however, about the function of RBM5 and RBM10 splice 
variants in non-transformed cells, and whether their observed role in transformed cells is 
a cause or a consequence of the transformed state. The present study provides initial 
evidence as to the role of Rbm5 and Rbm10 in a non-transformed system. First, it shows, 
for the first time, that Rbm5 splice variants Rbm5+5+6 and Lust are in fact expressed in 
rat, and throughout rat skeletal and cardiac myoblast differentiation. Secondly, this 
investigation demonstrates that Rbm5, Rbm10v1 and Rbm10v2 are expressed at both the 
mRNA and protein level in rat muscle cells and throughout rat skeletal and cardiac 
myoblast differentiation. Similarities between Rbm5+5+6 and Lust mRNA expression 
profiles during skeletal muscle differentiation suggest that both variants are involved in 
similar processes throughout differentiation, and/or work to regulate each other. In 
cardiac differentiation, however, only Lust was shown to have a potentially important 
role, with its expression levels remaining unchanged throughout differentiation, while 
those of Rbm5+5+6 declined. Significant changes in expression were observed for Rbm5 
and Rbm10v1 protein only during skeletal muscle differentiation, whereas changes in 
Rbm10v2 protein were observed during both skeletal and cardiac muscle differentiation. 
However, these variations in Rbm5, Rbm10v1 and Rbm10v2 protein expression did not 
correlate with their mRNA expression results. This suggests that Rbm5, Rbm10v1 and 
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Rbm10v2 undergo important post-transcriptional or translational regulation during 
differentiation, suggesting in turn that they may play an important role in lineage 
determination.  
In all, temporal changes in Rbm5 and Rbm10 splice variant expression throughout 
both skeletal and cardiac myoblast differentiation hint that these variants may be playing 
a similar role in differentiation as in transformed cells, including influencing alternative 
splicing, apoptosis and/or cell cycle arrest; however, it is important to note that these 
expression changes could be indicative of the involvement of Rbm5 and Rbm10 in 
completely different, potentially differentiation-specific, cellular processes. Based on the 
expression data alone, it is not yet possible to link a function to Rbm5 and Rbm10 during 
myoblast differentiation. Nonetheless, this work did lay the groundwork for future 
functional studies. 
To more thoroughly assess the function of Rbm5 and Rbm10 during myoblast 
differentiation, future studies could include a systematic analysis of the effects of Rbm5 
and Rbm10 inhibition on the physiology of both skeletal and cardiac myoblast 
differentiation, and the expression of cell cycle and apoptosis regulatory factors. Protein: 
RNA binding studies, particularly focusing on a comparison between the days of 
differentiation where the Rbm protein of interest is significantly differentially expressed, 
would also help to give a more precise understanding of the exact mechanism of action of 
the protein. All in all, uncovering the role of Rbm5 and Rbm10 in non-transformed 
systems will help to acquire a wider range of knowledge regarding the function of these 
proteins and, consequently, a better understanding of their importance in transformed 
cells. This information could potentially guide future therapeutic endeavours to ensure 
maximum efficacy in cancer cells and minimal effects in normal tissue. 
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Appendix. Post-transcriptional regulation of Rbm5 expression in H9c2 
cells 
Leslie C. Sutherland, Julie J. Loiselle and Sarah J. Tessier  
 
Summary 
 
Having examined the expression of Rbm5 during myoblast differentiation and found 
sustained protein levels throughout cardiac myocyte development, we decided to 
determine if full-length Rbm5 expression was a cause or a consequence of differentiation. 
Our hypothesis was that if Rbm5 protein expression was necessary for cardiac myocyte 
development, then inhibition of expression would prevent myoblast differentiation into at 
least the cardiac lineage. Our objective was therefore to inhibit Rbm5 expression and 
examine the effect on H9c2 differentiation. Towards this end, stable knockdown myoblast 
clones and a transient knockdown population were generated. Expression analyses 
demonstrated a significant decrease in Rbm5 mRNA levels but, surprisingly, no effect on 
Rbm5 protein levels. When expression of the Rbm5 paralogue Rbm10 was examined, to 
ensure no off-target knockdown effect and investigate any possible compensatory effects, 
Rbm10 protein levels were found to be significantly elevated, in both the clones and the 
transiently transfected population. These results suggest that Rbm5 expression is 
regulated by a process that includes RNA sequestration and/or controlled translation, and 
that (a) Rbm5 function is compensated for by Rbm10, and/or (b) Rbm10 expression is 
regulated by Rbm5. We have developed a model to describe our findings, and suggest 
further experiments for testing its validity. Since upregulation of Rbm10 might 
compensate for downregulated Rbm5, and consequently might mask any potential 
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knockdown effect on cardiac differentiation, it could lead to incorrect conclusions 
regarding the importance of Rbm5 for this process. It is therefore imperative to determine 
how both Rbm5 and Rbm10 protein expression is regulated.  
 
Chapter A1. Introduction 
 
In general, the expression of RBM5 is highest in cells that have reduced proliferation 
such as aging cells (Geigl et al., 2004), dormant seeds (Sugliani et al., 2010) and in adult 
thymus compared to fetal liver (Drabkin et al., 1999), and lowest in highly proliferating 
cells, e.g., most cancers such as non-small cell lung cancers (Oh et al., 2002), vestibular 
schwannomas (Welling et al., 2002), prostate cancers (Zhao et al., 2012), stage III serious 
ovarian carcinomas (Kim et al., 2010), pancreatic cancers (Peng et al., 2013) and biliary 
tract cancers (Miller et al., 2009). In fact, RBM5 was shown to one of nine genes down 
regulated in metastasis and part of the 17 common gene signatures associated with 
metastasis in various solid tumour types (Ramaswamy et al., 2003). The triggers for these 
expression fluctuations are unknown; however, using cancer cell lines, some of the 
mechanisms by which RBM5 expression can be regulated have been identified. For 
instance, RBM5 can be downregulated at the transcriptional level by a process that 
involves the read-through of polymerase from the upstream RBM6 gene and the 
consequent generation of “transcription-induced chimeras” (Wang et al., 2007).  Changes 
in RBM5 expression also occur via the regulation of alternative splicing, a role played by 
HER2 (Rintala-Maki et al., 2007) and potentially the antisense non-coding RBM5-related 
factor, LUST (Rintala-Maki & Sutherland, 2009). Post-transcriptionally, RBM5 can be 
differentially phosphorylated (Shu et al., 2007). 
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Changes in RBM5 expression levels are associated with changes in both the expression 
level and the alternative splicing of downstream transcripts. For example, overexpression 
of RBM5 in the human leukemic cell line CEM-C7 was associated with altered 
expression of 35 genes, including cyclin-dependant kinase 2 (CDK2) and signal 
transducer and activator of transcription 5B (Stat5b), which are involved in processes 
such as G1/S transition and apoptosis, respectively (Mourtada-Maarabouni et al., 2006). 
Knockdown of RBM5 was associated with altered expression of many genes in a number 
of different cell lines (a normal lung epithelial cell line (BEAS-2B), a normal breast 
epithelial cell line (MCF-10A) and three different lung cancer cell lines with varying 
RBM5 expression levels (A549, Calu-6 and NCI-H1299)), notably increasing the 
expression of genes involved in cell adhesion, migration and motility, processes 
important to metastasis (Oh et al., 2010).  In addition, in the MCF-7 breast 
adenocarcinoma cell line, RBM5 and TNF-α expression were shown to be positively 
correlated, TNF-α being an important apoptosis regulatory factor (Wang et al., 2012). 
RBM5 also regulates alternative splicing of pre-mRNAs involved in apoptosis (exclusion 
of caspase-2 exon 9 (Fushimi et al., 2008), FasR exon 6 (Bonnal et al., 2008) and c-FLIP 
exon 7 (Bonnal et al., 2008)), seed maturation (the inclusion of an ABIα/β exon (Sugliani 
et al., 2010)), muscular dystrophy (exclusion of Dytrophin exons 40 and 72 (O’Leary et 
al., 2009)) and immunoglobulin diversification (exclusion of AID exon 4 (Jin et al., 
2012)).     
Is it important to note that RBM5 shares highest homology with another RBM protein, 
RBM10 (Sutherland et al., 2005). In fact, RBM5 and RBM10 are approximately 50% 
homologous at the protein level in both human and rat. Also, endogenous RBM5 and 
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RBM10v1 protein expression levels have been shown to be significantly positively 
correlated in primary breast cancer samples (Rintala-Maki et al., 2007). 
In this mini-study we set out to determine the importance of Rbm5 to myoblast 
differentiation by manipulating Rbm5 expression levels. Rbm10 mRNA and protein 
expression levels were examined, to rule out off-target knockdown effects. The 
interesting observations that were made have been incorporated into a model that will be 
tested in future experiments. Based on our findings, we determined that any study 
involving a manipulation of Rbm5 expression levels to determine its importance during 
myoblast differentiation will first require a more thorough understanding of the 
relationship between Rbm5 and Rbm10. The results reported here constitute our initial 
attempts to gain this understanding, prior to future functional/physiological studies. 
 
Chapter A2. Materials and methods 
 
A2.1. Stable knockdown. Culture of H9c2 cells prior to transfection was performed as 
described in Chapter 2. At 24 hours prior to transfection, cells were passed in 100 mm 
plates (Sarstedt, Montreal, QC) to be approximately 35% confluent at the time of 
transfection. Twenty four hours following the appropriate plating, 12 µL of 
Lipofectamine 2000 (Life Technologies, Burlington, ON) was mixed with 1.5 mL of 
Opti-MEM reduced serum medium with GlutaMAX, and incubated at room temperature 
for five minutes. The appropriate shRNA construct (12 µg) was also mixed with 1.5 mL 
of Opti-MEM reduced serum medium with GlutaMAX, and incubated at room 
temperature for five minutes. Control samples were transfected with CSHCTR001-nU6 
shRNA scrambled control (GeneCopoeia, Rockville, MD, USA). Rbm5 knockdown 
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samples were transfected with both MSH039757-1 and MSH039757-6 Rbm5-specific 
shRNAs (6 µg of each) (GeneCopoeia) (Table 1). The Rbm5-specific shRNAs were 
100% homologous to both rat and mouse Rbm5 sequence. Following, the Lipofectamine 
2000+Opti-MEM and shRNA+Opti-MEM solutions were mixed together and incubated 
at room temperature for 35 minutes. The transfection solution was then added to the 
normal, serum-containing medium on the cells. Selection began 24 hours post-
transfection by treating cells with 1 µg/mL of puromycin. Cells were then cultured in 
antibiotic-containing medium to select for successful transfectants for at least 28 days 
following transfection and until they filled a 100 mm plate (Sarstedt). 
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Table 1. Small interfering RNA Rbm5 knockdown oligonucleotides. 
 
Type of 
oligonucleotide Oligonucleotide name 
Sense oligonucleotide sequence Location Homology to RBM10 Homology 
shRNA CSHCTR001-nU6  Scrambled N/A N/A 
      
 MSH039757-1 5’ GUAGUGGAAGAUAUGGUUC 3’  Exon 3 (12/19) 63% R M  
      
 MSH039757-6 5’ GAGCGAUAUUCGAGAAAUG 3’ Exon 4/5 (12/19) 63% R M H 
     
siRNA Trilencer-27mer 
universal scrambled 
negative control 
 
Scrambled N/A N/A 
      
 ON-TARGET RBM5 
duplex siRNA 
5’ GAGCGAUAUUCGAGAAAUG 3’ Exon 4/5 (12/19) 63% R M H 
     
H, R, M indicate homology to human, rat and mouse sequences, respectively. 
Sense sequence indicated for siRNA 
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A2.2. Transient knockdown. Culture of H9c2 cells prior to transfection was performed as 
described in Chapter 2. Twenty four hours prior to transfection, cells were passed to 6-well plates 
(Sarstedt) so as to be 40% confluent at the time of transfection. Twenty four hours after 
appropriately plating cells, 5 µL of Lipofectamine 2000 Reagent (Life Technologies) was added 
to 245 µL of Opti-MEM reduced serum medium with GlutaMAX (Life Technologies), and 
incubated at room temperature for five minutes. The appropriate siRNA was also added to 245 
µL of Opti-MEM reduced serum medium with GlutaMAX, and incubated at room temperature 
for five minutes. The siRNA used for the control samples was Trilencer-27mer universal 
scrambled negative control siRNA duplex (OriGene, Rockville, MD, USA). For Rbm5 
knockdown samples, custom ON-TARGET RBM5 duplex siRNA (Dharmacon, ThermoFisher 
Scientific, Ottawa, ON) was used: sense sequence was 5’-GAGCGAUAUUCGAGAAAUG-3’ 
and antisense sequence was 5’-CAUUUCUCGAAUAUCGCUC-3’ (Figure 1 and Table 1). 
siRNAs were administered to cells as such, to a final concentration of 10 nM. Following their 5 
minute incubation, the Lipofectamine 2000+Opti-MEM and siRNA+Opti-MEM solutions were 
mixed together and incubated at room temperature for 20 minutes. Next, the transfection solution 
was added to the normal, serum-containing medium on the cells. Medium was not changed after 
addition of transfection solution, and cell pellets were collected at 72 hours post-transfection. 
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Figure 1. Position of shRNAs, siRNA, PCR primers and antibodies used in this study on the corresponding rat Rbm transcript. Exons are represented by 
correspondingly numbered dark grey blocks. Exon and intron sizes are not to scale. Approximate location of forward and reverse primers used for PCR are 
indicated by right and left facing arrows on the transcript in question.  Size of arrow does not correspond to primer length in relation to exon or intron length, but 
gives the approximate position of the primer within the given exon or intron. Rat-specific sequences were used for primer design. Approximate antibody binding 
sites are indicated by black ovals with grey slanted lines, and the corresponding antibody’s name is indicated. Grey zig-zags represent approximate location of 
indicated siRNA or shRNA on indicated variant. 
Rbm5  10 9 8 7 6 5 4 3 2 1 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
Rbm10 
Variant 1 
Rbm10 
Variant 2 
10 9 8 7 6 5 4 3 2 1 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
10 9 8 7 6 5 3 1 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Anti-RBM5 LUCA-15UK Antibody  
Anti-RBM5 Abcam Antibody  
Anti-RBM10 Bethyl Antibody  
4 
Anti-RBM10 Bethyl Antibody  
MSH039757-1 shRNA 
MSH039757-6 shRNA and ON-TARGET RBM5 duplex siRNA 
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A2.3. Transient overexpression. Procedure followed is the same as that described in Chapter 2, 
using human RBM5 in a pcDNA3 vector. 
 
A2.4. RNA expression analysis. RNA extraction and reverse transcription (RT) were performed 
as described in Chapter 2. End-point semi-quantitative PCR was used to analyze Rbm5, Rbm10v1 
and Rbm10v2 mRNA expression in all samples, instead of the more sensitive real-time 
quantitative PCR, since only dramatic changes in expression were of interest to us. Gapdh 
expression was also examined in all samples, via RT-PCR, to normalize results. No strand-
specific RT reactions were performed in this study since only the expression of full-length Rbm5 
was analyzed, not that of its sense-specific splice variants. PCR was performed using 1 µL of 
cDNA, 1 µL of the corresponding forward and reverse primers (10 µM) (AlphaDNA, Montreal, 
QC) (Table 2), 1 µL of dNTP (10 µM) (Life Technologies), 2 µL of 10X Buffer (New England 
Biolabs, Whitby, ON), 1 µL of Taq DNA Polymerase (500 U/mL) (New England Biolabs), and 
sterile distilled water for a total volume of 15 µL per reaction. PCR cycles were as follows: (1) 
one cycle of 95ºC for 5 minutes, (2) gene specific number of cycles of 95ºC for 30 seconds, 
primer-specific annealing temperature (Table 1) for 30 seconds, and 72ºC for 45 seconds, and (3) 
one final extension cycle of 72ºC for 10 minutes. Step 2 of the PCR program was repeated 24 
times for Gapdh amplification, and 38 times for Rbm5 and Rbm10 amplification. PCR products 
were separated by electrophoresis through a 2% Tris-acetate EDTA (TAE) agarose gel and 
stained with SYBR Safe DNA gel stain (Life Technologies). Densitometric analysis was 
performed using AlphaEase FC software (Alpha Innotec). Rbm5 and Rbm10 mRNA expression 
values were first normalized to the expression of Gapdh, the reference gene used. Next, the 
average of the normalized expression value obtained for all technical replicates of a same 
biological replicate was determined. This average normalized expression 
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Table 2. Primers for RT-PCR. 
 
Gene 
name Primers  Homology 
Gapdh Forward 5’ ACCACAGTCCATGCCATCAC 3’ R M H 
 Reverse 5’ TCCACCACCCTGTTGCTGTA 3’ R M H 
 Product size in rat 452 bp  
 Annealing Temperature 58˚C  
 Accession No. Rat: BC059110, Mouse: BC082592, Human: BC004109  
    
Rbm5 Forward 5’ ATGGGTTCAGACAAAAGAG 3’ R M H 
 Reverse 5’ GCATTGCAATGTGCTTTCCTTGA 3’ R M H 
 Product size 520 bp  
 Annealing Temperature 55˚C  
 Accession No. Rat: BC166477, Mouse: BC023854, Human: AF091263  
    
Rbm10 Forward 5’ ATTGGCTCCCGTCGAACTAACAGT 3’ R  
 Reverse 5’ ACTTCTCTCGGCGCTTGAAGTTCT 3’ R M 
 Product size in rat Rbm10v1: 916 bp, Rbm10v2: 682 bp  
 Annealing Temperature 63˚C  
 Accession No. Rat: NM_152861, Mouse: NM_001167776, Human: NM_152856 
H, R, M indicate homology to human, rat and mouse sequences, respectively
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value was then expressed as fold-change from the control sample of that biological replicate, and 
averaged for the various biological replicates. This gave the final expression value that was 
graphed. 
 
A2.5. Protein expression analysis. Protein extraction and quantification were performed as 
described in Chapter 2. Western blot analysis for protein expression was also performed as 
described in Chapter 2, with only the described Abcam and LUCA-15UK anti-rat-RBM5 primary 
antibodies used to analyze Rbm5 protein expression. Densitometric analysis was performed on 
the resulting blots using AlphaEase FC software to quantify expression. The resulting Rbm5 and 
Rbm10 protein expression values were first normalized to the expression of α-tubulin, the 
reference gene used. Following, the average of the normalized expression value for all technical 
replicates of the same biological replicate was determined. Next, the normalized expression 
values were expressed as fold-change from the control sample of the corresponding biological 
replicate. Finally, the normalized fold-change in expression obtained for the various biological 
replicates was averaged and graphed.  
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Chapter A3. Results  
 
A3.1. Rbm5 mRNA knockdown has no effect on Rbm5 protein levels 
 
One hundred and seventeen Rbm5 shRNA transfected H9c2 clones were obtained following 28 or 
29 days of selection in puromycin. All 117 clones were screened for Rbm5 mRNA expression. 
Three clones (Clones 87, 9 and 100) with significant decrease of Rbm5 mRNA expression 
(>80%), compared to the scrambled control, were chosen for further analysis, along with one 
clone (Clone 104) with partial knockdown (~10%) and one clone (Clone 12) with no visible 
knockdown (Figure 2A). Surprisingly, Rbm5 protein levels were not significantly decreased in 
any of the Rbm5 knockdown clones (Figure 2B). To rule out any possible clonal effect that could 
account for abnormal regulation of protein expression, a transient transfection using siRNA-
specific to Rbm5 sequence (but different from one of the shRNA sequences used) was carried 
out. Knockdown was only ~ 40% but, once again, there was no decrease in Rbm5 protein levels 
(Figure 3). To ensure that antibody affinity was not an issue, two different anti-RBM5 antibodies 
were used (Figure 3). 
 
A3.2. Rbm5 knockdown correlates with increased Rbm10 protein levels 
 
Since rat Rbm10 has 57% homology at the DNA level with Rbm5, to ensure no off-target effect 
of the theoretically Rbm5-specific sh/siRNAs on Rbm10 expression, Rbm10 expression was also 
examined in the knockdowns. Since stable and transient knockdown of Rbm5 could have resulted 
from different shRNA and siRNA sequences (Table 1), both stable and transient knockdowns 
were tested for off-target effects on Rbm10. Rbm5 shRNA and siRNA sequences were 19-mers 
with 7 mismatches to rat Rbm10, meaning they had 63% similarity. In the clones, at the RNA 
level (Figure 4A), Rbm10v1 expression did not change  
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Figure 2. Rbm5 expression in shRNA stably transfected H9c2 clones. Control refers to sample 
transfected with scrambled control shRNA. (ŧ) beside a clone’s name indicates that Rbm5 mRNA 
expression in that clone showed a decrease of 50% or more compared to the scrambled control. A. 
Quantification of RT-PCR results for Rbm5 expression in H9c2 control, and stable RBM5 knockdown 
clones. Rbm5 expression values were first normalized to Gapdh and then expressed as fold-change from the 
control sample (scrambled siRNA transfectant). Data represents results from technical duplicates of one 
biological replicate. Error bars indicate standard error. Statistical significance was evaluated in comparison 
with the control sample with a Student’s unpaired t-test (* indicates p < 0.05, and ** indicates p < 0.01). B 
(i). Western blots of protein samples from H9c2 control and stable RBM5 knockdown clones. Blots were 
probed with Abcam anti-RBM5 primary antibody, stripped and probed for α-tubulin (used as a reference 
gene). Precision Plus ladder was used, and ladder values refer to weight in kDa. B (ii). Quantification of 
Western blot results for Rbm5 protein expression in H9c2 control and stable RBM5 knockdown samples. 
Expression was normalized to α-tubulin and expressed as fold-change from the control sample. Values 
represent results from B(i) blot.
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α-tubulin 
Rbm5 
** 
(ii) 
* 
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Figure 3. Rbm5 expression in siRNA transiently transfected H9c2 cells. H9c2 transient scramble and 
Rbm5 siRNA transfected cells (collected at 72 hours post-transfection). A (i). RT-PCR results for Rbm5 
and Gapdh amplification. Results are representative of technical duplicates performed from one biological 
replicate. (ii). Quantification of RT-PCR results from (i). Values normalized to Gapdh. Data represent 
results from technical duplicates, and error bars indicate standard error. Statistical significance was 
evaluated with a Student’s unpaired t-test (** indicates p < 0.01). B and C. Western blots of protein 
samples. Blots were probed with Abcam (B (i)) and LUCA-15UK (C (i)) anti-RBM5 primary antibodies, 
respectively. Blots were then stripped and probed for α–tubulin (used as reference gene). Ladder values 
refer to weight in kDa. B (ii) and C(ii). Quantification of Western blot results for Rbm5 protein expression 
as determined with Abcam (B (ii)) and LUCA-15UK (B(ii)) anti-RBM5 primary antibodies, respectively. 
Expression normalized to α-tubulin and expressed as fold-change from the control sample. Values represent 
results from B(i) and C(i), respectively.  
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Figure 4. Rbm10 expression in stable H9c2 Rbm5 knockdown clones.  
Control refers to scrambled control transfection. (ŧ) beside a clone’s name indicates that it showed a 
decrease in Rbm5 mRNA expression of 50% or more (successful Rbm5 knockdown at the mRNA level). A. 
Quantification of RT-PCR results for Rbm10 expression in H9c2 control, and stable RBM5 shRNA 
transfected clones. Values were first normalized to Gapdh and then expressed as fold-change from the 
control sample (scrambled siRNA transfectant). Data represents results from technical duplicates from one 
biological replicate, and error bars indicate standard error. B. (i) Western blot of protein samples from H9c2 
control and stable RBM5 knockdown clones. Blots were probed with Bethyl anti-RBM10 primary antibody, 
stripped and probed for α-tubulin (used as a reference gene). Precision Plus ladder was used, and ladder 
values refer to weight in kDa. (ii) Quantification of Western blot results for Rbm10 protein expression in 
stable RBM5 knockdown clones. Expression was normalized to α-tubulin and expressed as fold-change 
from the control sample. Values represent results from technical duplicates performed on one biological 
replicate. Statistical significance was evaluated in comparison with the control sample using a Student’s 
unpaired t-test (* indicates p < 0.05, and ** indicates p < 0.01). 
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significantly amongst any of the clones or from the control. Rbm10v2 expression, on the 
other hand, significantly decreased in all of the clones with the most significant Rbm5 
RNA knockdown (Clones 87, 9 and 100). At the protein level (Figure 4B), Rbm10v1 and 
Rbm10v2 expression was surprising increased, but only in the Rbm5 clones with the most 
significant Rbm5 RNA knockdown. Additionally, Rbm10v1 and Rbm10v2 protein 
expression was unexpectedly decreased in Clone 12, which had showed no change in 
Rbm5 mRNA expression levels as a result of knockdown. Contrary to the results in the 
stable Rbm5 knockdowns, in the transient Rbm5 knockdown, Rbm10v2 mRNA 
expression was significantly increased, compared to the scrambled control (Figure 5A). 
Similar to the stable knockdowns, both Rbm10v1 and Rbm10v2 protein expression 
increased (2-fold) compared to the scrambled control (Figure 5B). Knockdown data are 
summarized in Table 3. It is important to note that all experiments should be performed in 
biological triplicates before any conclusions can be made. 
 
A.3.3. Rbm5 overexpression does not correlate with decreased Rbm10 protein levels  
 
Since inhibition of Rbm5 RNA correlated with increased expression of RBM10v1 and 
RBM10v2 protein in both stable and transient knockdowns, we sought to determine if the 
reverse were true, and overexpression of Rbm5 correlated with decreased Rbm10 
expression. Transient overexpression of RBM5 mRNA and protein from the human 
cDNA sequence (which has approximately 80% homology with rat) was confirmed 
(Figure 6), but Rbm10v1 and Rbm10v2 mRNA and protein expression levels remained 
unchanged, compared to the scrambled control transfectants (Figure 7).  
A-17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Rbm10 expression in siRNA transiently transfected H9c2 cells.  
A. Quantification of RT-PCR results for Rbm10 mRNA expression in H9c2 control, and Rbm5 transient 
knockdown (KD) samples. Values normalized to Gapdh and expressed as fold-change from the control 
sample (scramble siRNA transfectant). Data represent results from technical duplicates, and error bars 
indicate standard error. Statistical significance was evaluated with a Student’s unpaired t-test (** indicates p 
< 0.01). B. (i) Western blot of protein samples from H9c2 cells transiently transfected with a scrambled 
control, or Rbm5 siRNA (samples collected at 72 hours post-transfection). Blots were probed with Bethyl 
anti-RBM10 primary antibody, stripped and probed for α-tubulin (used as reference gene). Precision Plus 
ladder was used, and ladder values refer to weight in kDa. (ii). Rbm10 protein expression in H9c2 control, 
and Rbm5 transient KD samples. Results obtained from quantification of Western blot results from (i). 
Expression normalized to α-tubulin and expressed as fold- change from the control sample. Values 
represent results from one technical replicate. 
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Table 3. Summary of H9c2 knockdown expression level data, expressed as a percentage of the scrambled 
control 
 
 Stables † Transient ‡ 
 Clone 87 Clone 9 Clone 100 Clone 104 Clone 12  
Rbm5 
RNA 19 7 17 90 100 59 
protein 94 101 86 81 93 118 
Rbm10v1 
RNA 65 95 85 50 141 124 
protein not analysed 137 136 106 81 198 
Rbm10v2 
RNA 14 36 19 83 151 190 
protein not analysed 135 171 102 75 224 
† One sample, analysed in duplicate for RNA. 
‡ One transient transfection, analysed in duplicate for RNA. 
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Figure 6. Rbm5 expression in transient RBM5 overexpression samples. 
Control refers to samples transiently transfected with scrambled control pcDNA3, and RBM5OE refers to 
samples transiently transfected with pcDNA3.RBM5 (RBM5 overexpression (OE) samples). Samples were 
collected at 48 hours post-transfection. (A) Quantification of RT-PCR results for Rbm5 expression in H9c2 
control, and transient Rbm5 OE samples. Values were normalized to Gapdh and expressed as fold-change 
from the control sample. Data represent results from technical duplicates performed on biological 
triplicates. Error bars indicate standard error. B (i) Western blot of protein from H9c2 control and RBM5 
transient OE samples. Blots were probed with Abcam anti-RBM5 primary antibody, stripped and probed for 
α-tubulin (used as reference gene). Precision Plus ladder was used, and ladder values refer to weight in kDa. 
Results shown are representative of results obtained from technical duplicates performed on biological 
triplicates. (ii) Quantification of Western blot results for Rbm5 protein expression in H9c2 control and 
transient RBM5 OE samples. Expression normalized to α-tubulin and expressed as fold-change from the 
control sample. Values represent results from biological triplicates, performed in technical duplicate. 
Statistical significance was evaluated in comparison with the control sample with a Student’s unpaired t-test 
(** indicates p < 0.01).  
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Figure 7. Rbm10 expression in H9c2 transient RBM5 overexpression samples.  
Control refers to samples transiently transfected with scrambled control pcDNA3, and RBM5OE to samples 
transiently transfected with pcDNA3.RBM5 (RBM5 overexpression (OE) samples). Transfection samples 
were collected at 48 hours post-transfection. A. Quantification of RT-PCR results for Rbm10v1 and 
Rbm10v2 mRNA expression in H9c2 control, and transient RBM5 OE samples. Values were normalized to 
Gapdh and expressed as fold-change from the control sample. Data represent results from biological 
triplicates, performed technical duplicates. Error bars indicate standard error. B. (ii) Western blot for Rbm5 
protein expression in H9c2 control and transient RBM5 OE samples. Blots were probed with Bethyl anti-
RBM10 primary antibody, stripped and probed for α-tubulin (used to as a reference gene). Precision Plus 
ladder was used, and ladder values refer to weight in kDa. Results shown are representative of results 
obtained for biological triplicates performed in technical duplicate. (ii) Quantification of Western blot 
results for Rbm10 protein expression in H9c2 control and transient Rbm5 OE samples. Expression 
normalized to α-tubulin and expressed as fold-change from the control sample. Values represent results 
from biological triplicates, performed in technical duplicate. Statistical significance was evaluated in 
comparison with the control sample with a Student’s unpaired t-test. No statistical significances of p < 0.05 
were observed.
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Chapter 4A. Discussion 
 
Our results suggest the following: 
 
A4.1. Only a small quantity of Rbm5 mRNA is translated 
 
Knockdown of Rbm5 mRNA is not reflected at the protein level. Lack of a positive 
correlation between Rbm5 RNA and protein expression in the transient transfections 
could possibly relate to the fact that (a) Rbm5 protein is very stable, or (b) the mRNA was 
only inhibited by 40%. When combined with the lack of a correlation in the stable clone 
observations (where mRNA was inhibited by 80-93%), the data suggest that unchanged 
Rbm5 protein expression levels in the stable clones was not due to any possible clonal 
effect but to a more general phenomenon. One possible explanation for this lack of 
correlation between Rbm5 mRNA and protein expression levels in the knockdown 
experiments is that only a fraction of endogenous Rbm5 mRNA is actually translated into 
protein. Transfection of shRNA complementary to a sequence of Rbm5 mRNA lead to 
degradation of up to 90% of the Rbm5 mRNA (Figure 8), but the ~ 10% that was left 
might be all that is normally translated in the wild-type myoblasts. One possible reason to 
account for the fact that only a small portion of Rbm5 mRNA may be translated is that 
messenger ribonucleoproteins (mRNPs) may be involved in sequestering the majority of 
Rbm5 mRNA in H9c2 cells. Precedent for this occurs in Xenopus oogenesis, where 80% 
of maternal mRNAs are sequestered in mRNP storage particles, and translation is 
inhibited until specific time-points during early embryogenesis when the mRNAs are 
recruited to ribosomes and finally translated (Spirin, 1966; Tafuri & Wolffe, 1993). A 
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second precedent occurs in P19 murine embryonic carcinoma cell differentiation, where 
the composition of mRNP-sequestered mRNAs changes following exposure to 
differentiation-inducing stimuli (Tenenbaum et al., 2000). Furthermore, in satellite cells, 
transcripts of Myf5, an important regulator of myogenesis, have been shown to be 
sequestered in mRNP granules. Upon activation of the satellite cells these granules 
dissociate, leading to liberation of Myf5 transcripts and consequently higher levels of 
Myf5 (Crist et al., 2012). This regulatory mechanism thus allows quiescent satellite cells 
to transcribe Myf5 without activating differentiation. A similar mechanism could be 
occurring in the H9c2 cells, which would explain not only why 90% knockdown of Rbm5 
mRNA is not reflected at the protein level, but why the changes in Rbm5 protein levels 
during cardiac differentiation were not positively correlated with changes in Rbm5 
mRNA levels (i.e., during differentiation, it is not the total amount of Rbm5 mRNA in the 
cell that is important but the amount that is not sequestered, and thus available for 
translation).  
In the overexpression experiments exogenous human RBM5 mRNA was translated. If our 
sequestering hypothesis is correct, this result suggests that either (a) the cell could 
distinguish between exogenous RBM5 and endogenous Rbm5 transcript, or (b) there was 
a finite quantity of Rbm5 message that could be sequestered, a quantity that might be 
regulated by levels of endogenous Rbm5 protein or Rbm10 mRNA/protein levels. 
 
A4.2. Regulation of Rbm5 protein expression in H9c2/myoblasts has unique 
characteristics  
 
Correlations between RBM5 expression at both the mRNA and protein levels have been 
examined in breast (Oh et al., 2002; Rintala-Maki et al., 2007), lung (Liang et al., 2012) 
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and pancreatic (Peng et al., 2013) non-tumour and tumour tissue, and various cell lines 
including A549 (lung adenocarcinoma) (Li et al., 2012; Oh et al., 2010), Calu-6 (possibly 
lung carcinoma) (Oh et al., 2010), NCI-H1299 (non-small cell lung carcinoma) (Oh et al., 
2010), U2OS (osteosarcoma) (Kobayashi et al., 2011), PC-3 (prostate adenocarcinoma) 
(Zhao et al., 2012),  BEAS-2B (immortalized human bronchial epithelial cells) (Oh et al., 
2010), HEK293 (human embryonic kidney cells) (Fushimi et al., 2008), MCF-10A 
(immortalized epithelial cells derived from human fibrocystic mammary tissue) (Oh et al., 
2010) and those of various mantle cell and follicular lymphomas (Weinkauf et al., 2007): 
a positive correlation between mRNA and protein expression levels was consistently 
observed. Only in non-tumour breast tissue was a positive correlation between RBM5 
mRNA and protein expression not observed (Rintala-Maki et al., 2007). Therefore, the 
mechanism suggested above in which only a percentage of Rbm5 mRNA is translated, 
and the rest is sequestered (perhaps in mRNPs) may be a restricted phenomenon that 
occurs in, for example, particular cell types or in cells with certain growth characteristics, 
including rat myoblasts.  
 
A.4.3. Decreased Rbm5 mRNA levels regulate Rbm10 protein expression  
 
It was interesting to note that, despite unchanged levels of Rbm5 protein, Rbm10 protein 
levels went up. This observation was particularly interesting in view of the fact that 
Rbm10v2 mRNA levels significantly decreased in the stable KDs. Any potential off-target 
effect of Rbm5 shRNA on Rbm10 was considered highly unlikely once the elevated levels 
of Rbm10 protein were observed. The results suggest a complex regulatory mechanism 
linking degradation of Rbm5 mRNA with Rbm10 protein expression.   
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We could postulate that depletion of Rbm5 mRNA “reserves” triggered an increase in 
Rbm10v2 protein stability (Figure 8). Even though there was no decrease in Rbm5 
protein, the cell anticipated this might be the case, and stabilized Rbm10. The difference 
in Rbm10v2 mRNA expression in the transient versus the stable Rbm5 knockdowns could 
have resulted from decreases in reserve Rbm5 mRNA that initially triggered increases in 
both transcription and translation of Rbm10 but, over time (i.e., in stables), a decrease in 
Rbm10 mRNA in order to avoid increasing Rbm10 protein levels too much. In this 
scenario, higher reserves of Rbm10 protein would have been generated, potentially to 
more rapidly respond if Rbm5 mRNA levels decreased further.  
 
A4.4. Model  
 
Based on the results of the Rbm5 knockdown and overexpression experiments, we 
hypothesize that the majority of Rbm5 transcripts are sequestered in the nucleus, possibly 
in mRNPs, and unavailable for translation. Release of sequestered transcripts would occur 
at certain points during differentiation, as required. Therefore, this could be the post-
transcriptional mechanism regulating Rbm5 expression throughout H9c2 skeletal and 
cardiac myoblast differentiation suggested by results in the corresponding thesis. 
Furthermore, since Rbm10 protein expression is increased upon reduction of Rbm5 
mRNA, we hypothesize a mechanism tasked with regulating Rbm5 mRNA levels, in 
order to ensure sufficient quantities of reserve material. Upon depletion, or at least partial 
depletion, of this stock, the mechanism rapidly increases Rbm10 mRNA and protein 
levels, in order to ensure the cell cycle, apoptosis and alternative splicing are  
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Figure 8. Model for regulation of Rbm5 and Rbm10 protein expression in H9c2 cells. 
In growing H9c2 cells, only 10% of Rbm5 mRNA transcripts are translated, with the remaining transcripts remaining sequestered in the cell, preventing their 
translation. A regulatory mechanism (represented by the black box) surveys Rbm5 mRNA levels in the cell to ensure that adequate stocks are maintained. Upon 
depletion of Rbm5 stocks, the mechanism increases levels of Rbm10 to compensate. 
10% is translated  into a protein product 
Sequestered 
and not 
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Rbm5 mRNA Rbm5 protein 
Translation 
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adequately regulated. This assumes that Rbm10 can, at least partially, compensate for 
Rbm5 functions in myoblasts (Figure 8).  
To test the validity of this model, the following experiments could be carried out. First, 
additional Rbm5 transient knockdowns should be generated (current model is based only 
on results from one biological replicate) in order verify that the differences observed 
regarding Rbm10 expression in the Rbm5 transient vs. stable knockdown samples are 
reproducible. Additional Rbm5 knockdown experiments could also be performed, using 
different siRNA and shRNA sequences, to further confirm our results. Other experiments 
could include knockdown and overexpression of Rbm10 in H9c2 cells and evaluation of 
Rbm10 and Rbm5 mRNA and protein expression levels in these samples. This would give 
us more information concerning the potential compensatory mechanism/functional 
overlaps of Rbm5 and Rbm10. Also, overexpression using rat Rbm5 instead of human, to 
begin to determine if there might possibly be a finite amount of Rbm5 that can be 
sequestered, and if perhaps only rat Rbm5 transcripts are able to be sequestered in rat 
myoblasts. 
Furthermore, mRNPs could be isolated from rat myoblasts to determine if Rbm5 is indeed 
sequestered in such particles. mRNPs could also be isolated from samples taken 
throughout rat skeletal and cardiac myoblast differentiation to see if sequestered levels of 
Rbm5 change throughout differentiation (i.e., when Rbm5 protein levels change). Finally, 
mRNPs could be isolated from various cancer cell lines in order to determine if Rbm5 is 
also sequestered in such particles in transformed cells; Rbm5 mRNA and protein 
expression have been previously shown to coordinate in a number of transformed cell 
lines, therefore Rbm5 may not be sequestered in such particles in cancer cells.  
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Chapter 5A. Conclusion 
 
The results from this work suggest that Rbm5 is post-transcriptionally regulated in rat 
myoblasts. More specifically, the results suggest that the majority of Rbm5 RNA is 
somehow sequestered (but available for knockdown by siRNA), as that only a small 
portion is ever translated. Results from Rbm10 mRNA and protein expression in Rbm5 
knockdown and overexpression samples also suggest that there is a mechanism that 
tightly monitors Rbm5 mRNA levels, and increases Rbm10 levels to compensate for a 
reduction in Rbm5 mRNA. Therefore, as in transformed cells, Rbm5 and Rbm10 may 
influence similar cellular processes in myoblasts. Furthermore, this role may be of utmost 
importance, explaining the suggested strict regulation of Rbm5 expression in myoblasts.
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